Page last updated: 2024-12-08

netilmicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID441306
CHEMBL ID1572
SCHEMBL ID18763322
MeSH IDM0014673
PubMed CID60196266
CHEMBL ID3182570
MeSH IDM0014673

Synonyms (68)

Synonym
nsc-759586
netira
CHEMBL1572
BSPBIO_001202
NCGC00179265-01
BPBIO1_001324
PRESTWICK3_001101
AB00514048
C07657
netilmicin
1-n-ethylsisomicin
d-streptamine, o-3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1->6)-o-[2,6-diamino-2,3,4,6-tetradeoxy-.alpha.-d-glycero-hex-4-enopyranosyl-(1->4)]-2-deoxy-n1-ethyl-
(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4-amino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxy-cyclohexoxy]-5-methyl-4-(methylamino)tetrahydropyran-3,5-diol
DB00955
brn 5316582
o-(2,6-diamino-2,3,4,6-tetradesoxy-alpha-glycero-4-hexenopyranosyl-(1-4)-o-(3-desoxy-4-c-methyl-3-methylamino-beta-l-arabinopyranosyl-(1-6)-2-desoxy-n1-ethyl-d-streptamin
d-streptamine, o-3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl(1-6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-glycero-hex-4-enopyranosyl(1-4))-2-deoxy-n(sup 1)-ethyl-
netilmicina [inn-spanish]
vectacin
einecs 260-146-8
NTL ,
1-n-aethylsisomicin
netilyn
d-streptamine, o-3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl-(1-6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-alpha-d-glycero-hex-4-enopyranosyl-(1-4))-2-deoxy-n1-ethyl-
hsdb 3584
netilmicine [inn-french]
netilmicinum [inn-latin]
netilmicin [inn:ban]
netilmicin (inn)
netira (tn)
D08268
(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4-amino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol
netilmicine
netilmicina
netilmicinum
unii-4o5j85gjjb
nsc 759586
4o5j85gjjb ,
netilmicin [mi]
netilmicin [hsdb]
netilmicin [who-dd]
d-streptamine, o-3-deoxy-4-c-methyl-3-(methylamino)- .beta.-l-arabinopyranosyl-(1->6)-o-(2,6-diamino-2,3,4,6-tetradeoxy-.alpha.-d-glycero-hex-4-enopyranosyl-(1->4))-2-deoxy-n(sup 1)-ethyl-
netilmicin [vandf]
o-3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl-(1->4)-o-(2,6-diamino-2,3,4,6-tetradeoxy-.alpha.-d-glycero-hex-4-enopyranosyl-(1->6))-2-deoxy-n(sup 3)-ethyl-l-streptamine
netilmicin [inn]
DTXSID1048542
CIDUJQMULVCIBT-MQDUPKMGSA-N
SCHEMBL18763322
NCGC00179265-05
NCGC00179265-08
netilmicin,(s)
2-hydroxycyclohexyloxy)-5-methyl-4-
amino-3-((2s,3r)-3-amino-6-(aminomethyl)-
3,4-dihydro-2h-pyran-2-yloxy)-6-(ethylamino)-
(methylamino)tetrahydro-2h-pyran-3,5-diol
(2r,3r,4r,5r)-2-((1s,2s,3r,4s,6r)-4-
Q2553496
bdbm50470664
gtpl12159
(2r,3r,4r,5r)-2-{[(1s,2s,3r,4s,6r)-4-amino-3-{[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy}-6-(ethylamino)-2-hydroxycyclohexyl]oxy}-5-methyl-4-(methylamino)oxane-3,5-diol
EN300-7481433
cas-56391-57-2
tox21_110663
dtxcid6025484
dtxsid8045484 ,
NCGC00179265-03
tox21_110663_1
CHEMBL3182570

Research Excerpts

Overview

Netilmicin is a semi-synthetic aminoglycoside antibiotic used against a broad spectrum of Gram-negative bacteria. It was found to be an effective and well-tolerated antibiotic, and prophylactic treatment shortened the mean patient bed-stay.

ExcerptReferenceRelevance
"Netilmicin (NET) is an antibiotic widely used in healthcare and agriculture, but it can accumulate in the environment to threat human health. "( Selection and identification of a DNA aptamer for fluorescent detection of netilmicin.
Deng, Y; Geng, X; Pan, C; Shen, G; Wang, L; Xie, X; Yu, H; Zhu, J, 2022
)
2.39
"Netilmicin is a semi-synthetic aminoglycoside antibiotic used against a broad spectrum of Gram-negative bacteria. "( Development and validation of a RP-HPLC method for the estimation of netilmicin sulfate and its related substances using charged aerosol detection.
Joseph, A; Patel, S; Rustum, A, 2010
)
2.04
"Netilmicin is a new aminoglycoside antibiotic with pharmacological similarities to gentamicin, tobramycin and sisomicin. "( Netilmicin in the treatment of severe or complicated urinary tract infections.
Bailey, RR; Blake, E; Peddie, BA; Summerfield, MJ, 1980
)
3.15
"Netilmicin appears to be an effective and safe drug in the treatment of a variety of bacterial infections."( High dose netilmicin therapy of severe or chronic infections.
Digranes, A; Hellum, KB; Madsen, ST; Solberg, CO; Stokstad, S, 1980
)
1.38
"Netilmicin is a new semisynthetic aminoglycoside which was developed by Schering Corporation, USA, for the treatment of serious gram-negative and staphylococcal infections. "( Netilmicin: chemical development and overview of clinical research.
Herting, RL; Lane, AZ; Lorber, RR; Wright, JJ, 1980
)
3.15
"Netilmicin was found to be an effective and well-tolerated antibiotic, and prophylactic treatment shortened the mean patient bed-stay and hence costs incurred."( Prophylactic netilmicin in surgery.
Abbas, AM; Jones, RB; Rigby, CC; Zaman, MM, 1982
)
1.35
"Netilmicin may prove to be a useful agent, particularly for infections due to multiresistant Klebsiella or Serratia, or when prolonged aminoglycoside therapy is required."( Therapeutic experience with netilmicin.
Bruce, AW; Chadwick, P; Cooke, TD; Hardy, GJ, 1978
)
1.27
"Netilmicin is an effective aminoglycoside with a spectrum of antibacterial activity similar to that of gentamicin sulfate and it appears to be less nephrotoxic."( Netilmicin in the treatment of infections in patients with cancer.
Bodney, GP; Yap, BS, 1979
)
2.42
"Netilmicin appears to be an effective, safe agent for the therapy of serious infections."( Clinical evaluation of netilmicin therapy in serious infections.
Fu, KP; Jahre, JA; Neu, HC, 1979
)
1.29
"Netilmicin appears to be an efficacious aminoglycoside and the oto- and nephrotoxicity is low, if careful attention is paid to the renal function and the serum concentrations of the drug."( Netilmicin: clinical evaluation of efficacy and toxicity of a new aminoglycoside.
Christensson, P; Haeger, K; Juhlin, I; Nordström, L; Tjernström, O; Wallmark, E, 1979
)
2.42
"Netilmicin sulfate is a new aminoglycoside antibiotic currently undergoing clinical investigation. "( Comparative ototoxic liability of netilmicin and gentamicin.
Brown, RT; Brummett, RE; Fox, KE; Himes, DL, 1978
)
1.98
"Netilmicin is a semisynthetic aminoglycoside derived from sisomicin. "( Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Campoli-Richards, DM; Chaplin, S; Goa, KL; Sayce, RH, 1989
)
3.16

Effects

Netilmicin has a generally broader antibacterial spectrum than gentamicin, tobramycin, sisomicin or debekacin and is resistant to inactivation by phosphorylating and adenylylating enzymes. It is inactivated by all acetylases, apart from acetylase 3-I.

Netilmicin has a generally broader antibacterial spectrum than gentamicin, tobramycin, sisomicin or debekacin and is resistant to inactivation by phosphorylating and adenylylating enzymes. It is inactivated by all acetylases, apart from acetylase 3-I. NetilMicin has proved to be effective in Gram-negative infections of the urinary tract, skin and skin structure, and lower respiratory tract.

ExcerptReferenceRelevance
"Netilmicin has a generally broader antibacterial spectrum than gentamicin, tobramycin, sisomicin or debekacin and is resistant to inactivation by phosphorylating and adenylylating enzymes; however, it is inactivated by all acetylases, apart from acetylase 3-I."( Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.
Noone, P, 1984
)
1.38
"Netilmicin has a significantly better in vitro effectiveness against CONS than gentamicin."( Antibiotic susceptibility of blood culture isolates after nearly two decades with netilmicin and ampicillin in neonatal septicaemia.
Abrahamsen, TG; Finne, PH; Gaustad, P; Rønnestad, A, 1999
)
1.25
"Netilmicin has a generally broader antibacterial spectrum than gentamicin, tobramycin, sisomicin or debekacin and is resistant to inactivation by phosphorylating and adenylylating enzymes; however, it is inactivated by all acetylases, apart from acetylase 3-I."( Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.
Noone, P, 1984
)
1.38
"Netilmicin has a significantly better in vitro effectiveness against CONS than gentamicin."( Antibiotic susceptibility of blood culture isolates after nearly two decades with netilmicin and ampicillin in neonatal septicaemia.
Abrahamsen, TG; Finne, PH; Gaustad, P; Rønnestad, A, 1999
)
1.25
"Netilmicin has been the most frequently used aminoglycoside, although other agents such as gentamicin, amikacin, and sisomicin have been studied."( Once daily aminoglycoside dosing: maintained efficacy with reduced nephrotoxicity?
Ariano, RE; Zhanel, GG, 1992
)
1
"Netilmicin has been intramuscularly administered in once daily dose of 4.5 mg/kg (mean daily dose 294.3 mg) for a mean duration of 17.8 days."( [Netilmicin in a single daily dose for treatment of systemic infections].
Andreoni, M; Andreoni, S; Fortina, A; Franchino, L; Ricciardiello, PT, 1990
)
1.91
"Netilmicin has proved to be effective in Gram-negative infections of the urinary tract, skin and skin structure, and lower respiratory tract, as well as in intra-abdominal infections, septicaemia and other miscellaneous infections."( Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Campoli-Richards, DM; Chaplin, S; Goa, KL; Sayce, RH, 1989
)
2.44

Actions

ExcerptReferenceRelevance
"Netilmicin did not cause detectable renal or auditory damage."( Clinical pharmacology of netilmicin in preterm and term newborn infants.
Assael, BM; Chung, M; Gagliardi, L; Granati, B; Montini, C; Parini, R; Pollazzon, P; Radwanski, E; Rubaltelli, FF, 1985
)
1.29

Treatment

Netilmicin-treated Pseudomonas strains exhibited a lower level of hydrophobicity towards n-hexadecane. Treatment did not differ significantly in mean daily dose per kg body weight and days of therapy between the two treatment arms.

ExcerptReferenceRelevance
"Netilmicin-treated Pseudomonas strains exhibited a lower level of hydrophobicity towards n-hexadecane compared with non-treated strains, while netilmicin-treated S."( Effects on adhesiveness and hydrophobicity of sub-inhibitory concentrations of netilmicin.
Bonfiglio, G; Furneri, PM; Garozzo, A; Musumarra, MP; Russo, A; Scuderi, AC, 2003
)
1.27
"Netilmicin treatment did not differ significantly in mean daily dose per kg body weight and days of therapy between the two treatment arms."( Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone.
Bouter, KP; de Vries, PJ; Dorrestein, GC; Nortier, JW; ter Braak, EW; van der Vegt, SG; van Dijk, A; Verbrugh, HA; Verkooyen, RP, 1990
)
1.2
"treatment with netilmicin, gentamicin, sisomicin, and kanamicin at different doses were performed in albino guinea pigs of both sexes."( Histological evaluation of ototoxic reaction due to some aminoglycoside antibiotics.
Arpini, A; Bamonte, F; Parravicini, L, 1980
)
0.6

Toxicity

50 grams of cancellous bone impregnated with 100 mg/mL netilmicin solution was impacted in the hip or knee joint with no adverse effects. Morphologic study of the medial basilar papilla disclosed that both kanamycin and netil micin are toxic to the hair cells in this region.

ExcerptReferenceRelevance
" Netilmicin is less toxic to the VIIIth nerve than is gentamicin in all species tested."( Netilmicin: a review of toxicity in laboratory animals.
Luft, FC, 1978
)
2.61
" Netilmicin appears to be effective and safe in the treatment of aerobic gram-negative infections."( Clinical efficacy and toxicity of netilmicin in the treatment of gram-negative infections.
Buckwold, FJ; Fox, L; Harding, GK; Lank, B; Ronald, AR; Thompson, L, 1979
)
1.45
" However, the aminoglycosides displayed marked differences in the threshold dose required to produce toxic reactions, permitting the following ordering of toxicity: (most toxic) gentamicin greater than netilmicin = tobramycin greater than amikacin = kanamycin (least toxic)."( Comparative toxicity of intravitreal aminoglycoside antibiotics.
Caspers-Velu, L; D'Amico, DJ; Hanninen, LA; Kenyon, KR; Libert, J; Schrooyen, M; Shanks, E, 1985
)
0.46
" There were no adverse effects attributable to either drug."( Comparative clinical efficacy and safety of netilmicin and tobramycin in children with serious gram-negative infections.
Weippl, G, 1983
)
0.53
" Intermittent dosing of aminoglycosides, causing infrequent large maximum serum concentrations, may be less toxic and equally efficacious as frequent dosing."( Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin.
Bloxham, DD; Cash, HA; DiScenna, AO; Groden, DL; Grossniklaus, DA; Jacobs, MR; Klinger, JD; Luthe, MA; Powell, SH; Stern, RC; Thompson, WL, 1983
)
0.48
" Morphologic study of the medial basilar papilla disclosed that both kanamycin and netilmicin are toxic to the hair cells in this region."( Aminoglycoside ototoxicity in the chick (Gallus domesticus) inner ear: I. The effects of kanamycin and netilmicin on the basilar papilla.
Fermin, CD; Igarashi, M,
)
0.57
" Studies comparing netilmicin with gentamicin using the less toxic once-daily schedule are lacking."( Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial.
Büller, HR; Dreschler, WA; Kuijper, EJ; Prins, JM; Speelman, P; Tange, RA, 1995
)
0.88
"Aminoglycoside nephrotoxicity remains a common clinical problem and is the major cause of acute toxic renal failure in hospitalized patients."( Effects of diltiazem on netilmicin-induced nephrotoxicity in rabbits.
Amirault, P; Blanchet, F; Carbon, C; Heudes, D; Lortholary, O; Nochy, D; Seta, N, 1993
)
0.59
" The adverse event rate was non-significantly lower in the piperacillin/ tazobactam group compared to the co-amoxiclav/aminoglycoside group (2% vs."( Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia.
Grossenbacher, M; Imhof, E; Speich, R; Vogt, M; Zimmerli, W, 1998
)
0.3
" Hence, impaction of large amounts of netilmicin-impregnated bone may cause toxic netilmicin values in serum."( High local concentrations without systemic adverse effects after impaction of netilmicin-impregnated bone.
Aamodt, A; Benum, P; Bergh, K; Husby, OS; Persen, L; Witsø, E, 2004
)
0.82
"50 grams of cancellous bone impregnated with 100 mg/mL netilmicin solution was impacted in the hip or knee joint with no adverse effects."( High local concentrations without systemic adverse effects after impaction of netilmicin-impregnated bone.
Aamodt, A; Benum, P; Bergh, K; Husby, OS; Persen, L; Witsø, E, 2004
)
0.8
" The safety profile of the dexamethasone/netilmicin combination was excellent with no evidence of poor local tolerance or adverse reaction."( Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery.
Carstocea, B; Di Bella, A; Favero, A; Gafencu, O; Milazzo, G; Papa, V; Radulescu, C; Russo, S, 2007
)
0.97
"A new fixed combination of dexamethasone and netilmicin was effective and safe in controlling ocular inflammation after cataract surgery."( Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery.
Carstocea, B; Di Bella, A; Favero, A; Gafencu, O; Milazzo, G; Papa, V; Radulescu, C; Russo, S, 2007
)
0.96
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"Both the studied fixed combinations are safe and effective in controlling postoperative inflammation and preventing postoperative ocular infections."( Efficacy and safety of netilmycin/dexamethasone preservative-free and tobramycin/dexamethasone-preserved fixed combination in patients after cataract surgery.
Passani, A; Passani, F; Pianini, V; Rossi, GC, 2010
)
0.36
"A total of 162 adverse effects out of 3546 examinations (4,5%) were reported acutely: in group A (1778 examinations), they consisted of 47 reactive conjunctivitis, 3 cases of blepharoconjunctivitis, 30 of eyelids swelling, and 3 infectious conjunctivitis, compared to 39 cases of conjunctival injection, 3 blepharoconjunctivitis, 33 eyelids swelling and 4 infectious conjunctivitis in group B (1768 examinations)."( Safety and tolerability of ozonated-oils in liposome eyedrop in preterm eye examination.
Campagnoli, MF; Coscia, A; Maestri, A; Reibaldi, M; Scaramuzzi, M, 2022
)
0.72
"Ozonated-oils eyedrops should be considered a valid and safe alternative for the lubrification of the ocular surface and an adjuvant strategy to further minimize the risk of microbial contamination during screening for ROP."( Safety and tolerability of ozonated-oils in liposome eyedrop in preterm eye examination.
Campagnoli, MF; Coscia, A; Maestri, A; Reibaldi, M; Scaramuzzi, M, 2022
)
0.72

Pharmacokinetics

The bactericidal activities of arbekacin (ABK), vancomycin (VCM), gentamicin (GM) and netilmicin (NTL) in mixed culture with Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa were examined using an in vitro computer programmed pharmacokinetic simulation system. The potential protective effect of these agents on systemic infection in neutropenic mice was examined.

ExcerptReferenceRelevance
" The pharmacokinetic properties of netilmicin were evaluated in 101 newborn infants and related to birth weight, gestational age, chronological age, and route of administration."( Pharmacokinetic properties of netilmicin in newborn infants.
McCracken, GH; Siegel, JD; Thomas, ML; Threlkeld, N, 1979
)
0.83
" A three compartment open model was employed to calculate the pharmacokinetic parameters."( Multicompartment pharmacokinetics of netilmicin.
Follath, F; Spring, P; Vozeh, S; Wenk, M, 1979
)
0.53
" Pharmacokinetic studies revealed lower renal concentrations of netilmicin after repetitive administration."( [Netilmicin and tobramycin: comparative evaluation of pharmacokinetics, nephrotoxicity, and therapeutic efficacy in animal studies (author's transl)].
Abraham, M; Freiesleben, H; Marre, R; Sack, K, 1979
)
1.41
" Several linear relationships between pharmacokinetic parameters and renal function indicators were defined."( Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis.
Dugal, R; Pechere, JC; Pechere, MM,
)
0.45
"0 kg body weight in their first 2 weeks of life by the population pharmacokinetic approach."( Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations.
Fattinger, K; Follath, F; Olafsson, A; Vlcek, J; Vozeh, S; Wenk, M, 1991
)
1.72
" The pharmacokinetic study was performed in six elderly patients of both sexes, apparently in good general health, except for their urinary tract infections."( Effect and pharmacokinetics of netilmicin given as bolus intramuscular administration: an open comparative trial versus amikacin and fosfomycin in elderly patients affected by urinary tract infections.
Amprimo, MC; Caramalli, S; Cavalli, G; Franchino, L; Mantelli, M; Pollastrelli, E; Raiteri, F; Varese, LA, 1991
)
0.57
"A method is described to predict the efficacy of antibiotics at changing concentrations in vitro or in an experimental thigh infection in granulocytopenic mice from the activity at constant concentrations in vitro, using pharmacokinetic parameters."( A predictive parameter of antibacterial efficacy in vivo, based on efficacy in vitro and pharmacokinetics.
Mattie, H, 1990
)
0.28
" We approximated in mice the human pharmacokinetic profiles of netilmicin, ticarcillin and ceftazidime."( Simulation of human pharmacokinetic profiles in mice, and impact on antimicrobial efficacy of netilmicin, ticarcillin and ceftazidime in the peritonitis-septicemia model.
Gerber, AU; Segessenmann, C; Stalder, B; Stritzko, T, 1990
)
0.74
"To complement a study on aminoglycoside dosing regimen and ototoxicity in the guinea pig, we designed an experiment to examine: (1) the effect of dosing regimen on guinea pig pharmacokinetic parameters, and (2) possible differential accumulation after repeated intramuscular administrations of netilmicin and amikacin (150 mg/kg/day) for 7 days by 1 or 3 daily injections."( Aminoglycoside dosing regimen and pharmacokinetic parameters in the guinea pig.
Bamonte, F; Dionisotti, S; Kramer, WG; Leung, P; Ongini, E, 1990
)
0.45
" In patients with ascites, the same pharmacokinetic parameters were measured after the ascites had been cured."( [Pharmacokinetics of netilmicin in cirrhotic patients with or without ascites].
Denis, C; Denis, J, 1988
)
0.59
" Several relationships between pharmacokinetic parameters and renal function indicators are defined."( Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis.
Domingo, JV; García Díez, JM; Herrero, A; Mahiques, E; Rius Alarcó, F, 1988
)
0.6
"An in vitro pharmacokinetic model was used to study the comparative antibacterial activities of multiple-dose regimens of enoxacin and netilmicin."( Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.
Blaser, J; Groner, MC; Stone, BB; Zinner, SH, 1987
)
0.75
" The advantages and disadvantages of arbitrary, predictive, and pharmacokinetic methods of dosing determination are summarized."( Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services.
Bailie, GR; Mathews, A, 1987
)
0.27
"Tissue penetration may be an important pharmacokinetic determinant to achieve the chemotherapeutic efficacy of antimicrobial agents."( A mouse model for simultaneous pharmacokinetic and efficacy studies of antibiotics at sites of infection.
Renneberg, J; Walder, M, 1988
)
0.27
" During the hemodialysis sessions, the serum half-life of netilmicin decreased approximately 10-fold compared with the interdialysis periods."( Pharmacokinetics of netilmicin during hemodialysis: comparison of four artificial kidneys.
Domingo, JV; García-Díez, JM; Herrero, A; Mahiques, E; Rius Alarcó, F, 1988
)
0.84
" Twenty-four hours after the first period of this pharmacokinetic study, identical parameters were evaluated under dipyrone induced normothermic conditions."( Pharmacokinetics of ceftazidime and netilmicin in patients with sepsis.
Ganzinger, U; Grimm, G; Kleinberger, G; Laggner, A; Lenz, K; Schatz, F, 1987
)
0.55
"Our study aimed to determine the least number of samples that are required to obtain accurate pharmacokinetic parameters in neonates."( Ethics of drug studies in infants: how many samples are required for accurate estimation of pharmacokinetic parameters in neonates?
James, A; Koren, G; Long, D, 1987
)
0.27
" Concentrations in serum and urine were measured by radioimmunoassay, and concentrations in serum and urinary excretion rates were simultaneously fitted to a two-compartment pharmacokinetic model."( Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers.
Adelman, MH; Evans, EJ; Schentag, JJ; Winslade, NE, 1987
)
0.52
" The mean interdialysis half-life was 49."( Netilmicin pharmacokinetics in uremic patients undergoing hemodialysis.
Basile, C; Curino, E; Di Maggio, A; Lodeserto, C; Longo, S; Mingrone, G; Orbello, G; Scatizzi, A; Strippoli, P; Triarico, A, 1986
)
1.71
" The results of standard in vitro checkerboard tests for synergism were predictive of the initial (4 to 8 h) but not the final (24 to 28 h) assessment of drug interaction in the pharmacokinetic model."( Impact of netilmicin regimens on the activities of ceftazidime-netilmicin combinations against Pseudomonas aeruginosa in an in vitro pharmacokinetic model.
Blaser, J; Groner, MC; Stone, BB; Zinner, SH, 1985
)
0.67
" A three-fold interpatient variation in pharmacokinetic parameters was seen."( Pharmacokinetics of netilmicin in premature infants.
Bickers, RG; Kuhn, RJ; Nahata, MC; Powell, DA, 1986
)
0.59
" The pharmacokinetic profile of netilmicin is very similar to that of gentamicin."( Netilmicin sulfate: a comparative evaluation of antimicrobial activity, pharmacokinetics, adverse reactions and clinical efficacy.
Craig, WA; Gudmundsson, S; Reich, RM,
)
1.86
"To determine netilmicin pharmacokinetic parameters and to evaluate the use of a one-compartment pharmacokinetic model, 32 patients receiving netilmicin for suspected gram-negative sepsis were enrolled in our study protocol."( Clinical use of a one-compartment model for determining netilmicin pharmacokinetic parameters and dosage recommendations.
Crossley, KB; Rotschafer, JC; Russillo, NJ; Solem, LD; Strate, RG; Tofte, RW; Zaske, DE, 1983
)
0.88
" The serum half-life (t1/2), tended to show higher values in premature than in mature newborns, although this was not statistically significant."( Pharmacokinetic assessment of netilmicin in newborns and older children.
Bergan, T; Michalsen, H, 1982
)
0.55
" Detailed pharmacokinetic analysis of the plasma drug concentration-time data up to 36 h after the intravenous dose revealed that the pharmacokinetics of the aminoglycoside antibiotics can be best described as a three-compartment open model."( Comparative pharmacokinetics of aminoglycoside antibiotics in guinea pigs.
Assael, BM; Cavanna, G; Chung, M; Parravicini, L; Radwanski, E; Symchowicz, S, 1982
)
0.26
" The correlation between serum creatinine levels and the half-life of the antibiotics was found to be statistically significant."( Pharmacokinetics of amikacin, netilmicin and tobramycin in children with chronic renal failure.
Emre, S; Eti, S; Nayir, A; Sirin, A; Yeşilbek, T,
)
0.42
"The influence of the choice of pharmacokinetic model on subsequent determination of covariate relationships in population pharmacokinetic analysis was studied using both simulated and real data sets."( Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.
Beal, SL; Sambol, NC; Wade, JR, 1994
)
0.29
" In the iris and ciliary body the peak concentration was reached 1 h after shield application, netilmicin concentration decreased thereafter rapidly."( Collagen shields delivery of netilmicin: a study of ocular pharmacokinetics.
De Natale, R; Dorigo, MT; Miglioli, PA,
)
0.64
"The bactericidal activities of arbekacin (ABK), vancomycin (VCM), gentamicin (GM) and netilmicin (NTL) in mixed culture with Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa were examined using an in vitro computer programmed pharmacokinetic simulation system and also the protective effect of these agents on systemic infection in neutropenic mice was examined."( [Evaluation of bactericidal activity of arbekacin in mixed culture with MRSA and Pseudomonas aeruginosa using an in vitro pharmacokinetic simulation system].
Goto, S; Sugano, T; Takada, T; Takase, Y; Tsuji, A; Yamaguchi, K; Yoshida, T, 1994
)
0.51
" Pharmacokinetic parameters (half-life [5."( Fever and associated changes in glomerular filtration rate erase anticipated diurnal variations in aminoglycoside pharmacokinetics.
Belfayol, L; Bosio, AM; Boukari, M; Cherrier, P; Coulaud, JM; Fauvelle, F; Perrin, P; Petitjean, O; Tod, M, 1994
)
0.29
" A meta-analysis of the published pharmacokinetic data is required to build up a knowledge-based computer system for dosage adjustment in renal failure."( Nonparametric meta-analysis of published data on kidney-function dependence of pharmacokinetic parameters for the aminoglycoside netilmicin.
Buettner, P; Erdmann, K; Giehl, M; Keller, F, 1993
)
0.49
" The same total dose of netilmicin was administered as once-daily (24-micrograms/ml peaks) and thrice-daily (8 micrograms/ml) regimens in a pharmacodynamic in vitro model simulating exposure of Enterococcus faecalis to human serum kinetics."( Once-versus thrice-daily netilmicin combined with amoxicillin, penicillin, or vancomycin against Enterococcus faecalis in a pharmacodynamic in vitro model.
Blaser, J; Schwank, S, 1996
)
0.9
"The potential nephrotoxicity and pharmacokinetic parameters of netilmicin were investigated in rabbits after single and multiple dosage regimens (7 mg/kg/12 h) allometrically equivalent to a once-daily regimen of 5 mg/kg/24 h in man."( Study on pharmacokinetics and nephrotoxicity of netilmicin in rabbits using a new dosage regimen.
Arévalo, M; Colino, CI; Domínguez-Gil, A; Lanao, JM; López, FG; Navarro, AS; Santos, M,
)
0.63
"The pharmacokinetic interaction of Netilmicin and Piperacillin has been studied as well as the potential protective effect that Piperacillin exert on nephrotoxicity caused by Netilmicin, when both antibiotics are administered to rabbits by single and multiple dosage regimens."( Pharmacokinetic parameters of netilmicin and protective effect of piperacillin regarding nephrotoxicity caused by netilmicin.
Arévalo, M; Lanao, JM; López, FG; Sánchez Navarro, A; Santos Navarro, M; Zarzuelo Castañeda, A,
)
0.7
"To study the pharmacokinetics of netilmicin in Chinese haematology-oncology patients and to determine the pharmacokinetic differences, if any, between this patient subpopulation of Chinese and Caucasians."( Netilmicin pharmacokinetics in Hong Kong Chinese cancer patients.
Chan, AT; Chan, LS; Chang, S; Li, RC; Raymond, K; Wong, SY; Zhu, M, 1999
)
2.03
" Pharmacokinetic parameters were generated using the USC*PACK package based on specifics of the patients themselves and Caucasians matched for the same patients' parameters using the Bayesian alogrithms."( Netilmicin pharmacokinetics in Hong Kong Chinese cancer patients.
Chan, AT; Chan, LS; Chang, S; Li, RC; Raymond, K; Wong, SY; Zhu, M, 1999
)
1.75
" Direct application of Caucasian based population pharmacokinetic parameters to this subgroup of Chinese patients may not be appropriate and may result in underdose."( Netilmicin pharmacokinetics in Hong Kong Chinese cancer patients.
Chan, AT; Chan, LS; Chang, S; Li, RC; Raymond, K; Wong, SY; Zhu, M, 1999
)
1.75
" The influence of gestational and postnatal age, weight, Apgar score, and creatinine and urea plasma concentrations on the pharmacokinetic parameters was assessed."( Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method.
Merlé, Y; Pons, G; Semlali, A; Tréluyer, JM, 2000
)
0.58
" There was a large degree of inter-patient variability in serum concentrations and serum half-life (t1/2), volume of distribution (VD), area-under-the-curve (AUC), relative serum clearance (Clp) such that these parameters could not be correlated to age or weight."( Pharmacokinetics of once-a-day netilmicin (4.5 mg/kg) in neonates.
Bedford, KA; Dixon, JJ; Gosden, PE; Leaf, AA; Macgowan, AP; Speidel, BD, 2001
)
0.6
"Bi-compartmental pharmacokinetic parameters of netilmicin have been estimated from clinical data in urological surgery patients using a population approach."( Population pharmacokinetics of netilmicin in short-term prophylactic treatment.
Astobieta, A; Calvo, R; Jauregizar, N; Lukas, JC; Rodriguez Sasiain, JM; Wald, JA, 2003
)
0.86
"Our goal was to perform a pharmacokinetic analysis of netilmicin to develop the optimum dosage regimen of this antibiotic in premature neonates hospitalized in Neonate Intensive Care Unit of the Institute of Mother and Child in Warsaw."( [Pharmacokinetics of netilmicin in neonates].
Kaminska, E; Piekarczyk, A; Poszwinska, B; Rutkowska, M; Sosonowska, K; Taljanski, W,
)
0.7
"The mean of pharmacokinetic parameters for groups I, II, and III were defined respectively: t(0."( [Pharmacokinetics of netilmicin in neonates].
Kaminska, E; Piekarczyk, A; Poszwinska, B; Rutkowska, M; Sosonowska, K; Taljanski, W,
)
0.45
" All the calculated pharmacokinetic parameters in the premature neonate groups (group II and III) significantly differs from the parameters calculated for full-term neonates."( [Pharmacokinetics of netilmicin in neonates].
Kaminska, E; Piekarczyk, A; Poszwinska, B; Rutkowska, M; Sosonowska, K; Taljanski, W,
)
0.45
"The relationship between the volume of distribution, assessed according to the two-compartmental pharmacokinetic model, and extracellular water estimated by bioimpedance was studied in mechanically ventilated patients with sepsis and capillary leak."( Can bioimpedance determine the volume of distribution of antibiotics in sepsis?
Balik, M; Kolar, M; Pachl, J; Sedivy, J; Smejkalova, V; Waldauf, P, 2005
)
0.33
"In neonates with very low GA, the pharmacokinetic parameters of netilmicin determined after an intravenous loading dose were not dependent on GA when normalized to BW."( Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very low gestational age.
Beedgen, B; Haefeli, WE; Linderkamp, O; Mikus, G; Rengelshausen, J; Tsamouranis, K; Walter-Sack, I, 2006
)
0.89
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The clearance (Cl), serum half-life (t(1/2)), and volume of distribution (Vd) of aminoglycosides change during the neonatal life, and the pharmacokinetics of aminoglycosides need to be studied in neonates in order to optimise therapy with these drugs."( Clinical pharmacokinetics of aminoglycosides in the neonate: a review.
Pacifici, GM, 2009
)
0.35
" Netilmicin peak and trough serum concentrations were monitored and netilmicin pharmacokinetic parameters were compared with and without parenteral nutrition."( Netilmicin in the neonate: pharmacokinetic analysis and influence of parenteral nutrition.
Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009
)
2.71
"There were no statistically significant differences between the pharmacokinetic parameters of netilmicin (volume of distribution, elimination half-life, clearance) in critically ill neonates >32 weeks during the first week of life that received either fluid therapy or parenteral nutrition."( Netilmicin in the neonate: pharmacokinetic analysis and influence of parenteral nutrition.
Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009
)
2.01

Compound-Compound Interactions

Netilmicin was administered in combination with continuous infusions of amoxicillin, vancomycin, or penicillin against a bacterial biofilm adhering to glass beads. The antibacterial in vitro activity of piperacillin and tazobactam (in a concentration ratio of 8/1) was studied.

ExcerptReferenceRelevance
"The in vitro effects of Bay k 4999 in combination with gentamicin, tobramycin, amikacin sisomicin and netilmicin in bacteriostatic (MIC) and bactericidal (MBC) concentrations were compared using the checkerboard dilution technique against 20 different strains of Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and indole-positive-negative Proteus species."( In vitro efficacy of Bay k 4999, a new ureido-penicillin, in combination with aminoglycosides against Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Proteus strains.
Daschner, FD; Langmaack, H; Steffens, A, 1979
)
0.48
"To assess the possibility that non-aminoglycoside antibiotics may adversely affect the nephrotoxicity of the new semisynthetic aminoglycoside netilmicin, we gave ampicillin, carbenicillin, methicillin, cefamandole, and clindamycin, either singly or in combination with netilmicin, at two dose concentrations in rats."( Nephrotoxicity of netilmicin in combination with non-aminoglycoside antibiotics.
Hagstrom, GL; Luft, FC; Maxwell, DR; Sloan, RS; Yum, MN, 1978
)
0.79
"We studied the efficacy of sulbactam, a beta-lactamase inhibitor, in combination with ceftriaxone in vitro and in experimental endocarditis due to an Escherichia coli strain producing an extended-spectrum beta-lactamase most similar to SHV-2, a new mechanism of resistance to broad-spectrum cephalosporins among members of the family Enterobacteriaceae."( Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase.
Buré, A; Carbon, C; Caron, F; Fantin, B; Mohler, J; Pangon, B; Philippon, A; Potel, G; Vallée, E; Vallois, JM, 1990
)
0.28
" The patients received 24 courses of netilmicin (10 mg/kg/day) in combination with azlocillin (600 mg/kg/day), cefsulodin (200 mg/kg/day) or ceftazidime (150 mg/kg/day) for 9-14 days."( Serum and sputum concentrations of netilmicin in combination with acylureidopenicillin and cephalosporins in clinical treatment of pulmonary exacerbations in cystic fibrosis.
Hjelte, L; Malmborg, AS; Strandvik, B, 1989
)
0.83
" The bactericidal effect obtained with daptomycin in combination with aminoglycosides suggest that further evaluation of these combinations in enterococcal endocarditis could have a clinical interest if this bactericidal effect was confirmed by in vivo studies."( [Bactericidal activity of daptomycin and vancomycin alone or in combination with tobramycin, netilmicin or ampicillin against enterococcus].
Cordin, X; Duez, JM; Kazmierczak, A; Péchinot, A; Siébor, E, 1989
)
0.5
" MICs and MBCs of netilmicin alone and combined with azlocillin, mezlocillin and imipenem were studied."( In vitro activity of netilmicin alone and in combination with azlocillin, mezlocillin and imipenem against 149 coagulase-negative staphylococci.
Allocati, N; Cellini, L; D'Antonio, D; D'Eletto, MR; Di Girolamo, A; Piccolomini, R; Ravagnan, G, 1989
)
0.93
" When combined with gentamicin or netilmicin a bactericidal and synergistic killing was observed within 1-8 h in all strains except Str."( In-vitro activity of the new penems FCE 22101 and FCE 24362 alone or in combination with aminoglycosides against streptococci isolated from patients with endocarditis.
Dornbusch, K; Henning, C; Lindén, E, 1989
)
0.56
"Seven strains of Streptococcus faecalis, of which two possessed high-level resistance to streptomycin (MIC greater than or equal to 2000 mcg/ml), and two strains of Streptococcus faecium were evaluated with respect to killing-effect and duration of post-antibiotic effect (PAE) of ampicillin and vancomycin in combination with streptomycin, gentamicin, tobramycin and netilmicin."( Evaluation of the combination effects of ampicillin or vancomycin combined with streptomycin, gentamicin, tobramycin or netilmicin against enterococci.
Fuursted, K, 1989
)
0.65
"Over a two year period 174 evaluable episodes of fever in neutropenic patients were treated in a randomized study comparing four beta-lactam antibiotics, each given in combination with netilmicin."( A randomized trial of empirical antibiotic therapy with one of four beta-lactam antibiotics in combination with netilmicin in febrile neutropenic patients.
Blacklock, H; Corringham, R; Devereux, S; Guimaraes, M; Hann, I; Hoffbrand, AV; Prentice, HG; Sage, R; Stirling, L; Trikka, E, 1988
)
0.68
"We studied in vitro bactericidal effects of netilmicin combined with other antibiotics, comparing with that obtained with other aminoglycosides combinations."( [Antibacterial activity of netilmicin in combination with other antibiotics. Comparison with other aminoglycosides (author's transl)].
Chanal, M; Cluzel, M; Roussanne, MC; Sirot, D; Sirot, J, 1982
)
0.82
"The antibacterial in vitro activity of piperacillin and tazobactam (in a concentration ratio of 8/1) was studied in combination with netilmicin or amikacin by a microtiter checkerboard assay against 162 strains of Enterobacteriaceae."( [In vitro antibacterial activity of piperacillin-tazobactam in combination with netilmicin or amikacin against Enterobacteriaceae resistant to amoxicillin].
Chamard-Neuwirth, C; Cordin, X; Duez, JM; Kazmierczak, A; Pechinot, A; Siebor, E, 1995
)
0.72
"The antipseudomonal activities of ceftriaxone (CEF) or ceftazidime (CAZ), each combined with tobramycin (TOB) or netilmicin (NET), against 90 clinically significant Pseudomonas aeruginosa isolates were examined both by checkerboard and time-kill assays."( In vitro synergism of ceftriaxone combined with aminoglycosides against Pseudomonas aeruginosa.
Chow, AW; Gallimore, B; Laverdière, M; Poonia, K; Restieri, C, 1994
)
0.5
"In a prospective, randomized trial, netilmicin given once daily (OD) was compared in terms of efficacy and safety with the conventional 8-hourly dosing regimen (TD), both in combination with a broad spectrum beta-lactam, as initial empirical therapy for febrile neutropenic patients; the total daily dosage of netilmicin in each group was 6 mg/kg body weight."( Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients.
Gaus, W; Kern, WV; Kurrle, E; Moritz, T; Reichle, A; Rozdzinski, E; Schmeiser, T, 1993
)
0.83
" Netilmicin was administered in combination with continuous infusions of amoxicillin, vancomycin, or penicillin against a bacterial biofilm adhering to glass beads."( Once-versus thrice-daily netilmicin combined with amoxicillin, penicillin, or vancomycin against Enterococcus faecalis in a pharmacodynamic in vitro model.
Blaser, J; Schwank, S, 1996
)
1.51
" This study describes an improved LC method combined with pulsed electrochemical detection for the analysis of netilmicin."( Development and validation of an improved reversed-phase liquid chromatographic method combined with pulsed electrochemical detection for the analysis of netilmicin.
Adams, E; Hoogmartens, J; Manyanga, V, 2010
)
0.77
" Time-kill analysis was performed in three isolates to characterize the kill kinetics of SNH alone and in combination with the antibiotics that engendered synergy in checkerboard assays."( In vitro activity of sodium new houttuyfonate alone and in combination with oxacillin or netilmicin against methicillin-resistant Staphylococcus aureus.
Hu, X; Jiang, J; Li, X; Lu, X; Lu, Y; Ren, Z; Yang, X; You, X; Zhao, L, 2013
)
0.61
" In time-kill analysis, SNH at 1/2 MIC in combination with oxacillin at 1/128 to 1/64 MIC or netilmicin at 1/8 to 1/2 MIC decreased the viable colonies by ≥ 2log(10) CFU/mL."( In vitro activity of sodium new houttuyfonate alone and in combination with oxacillin or netilmicin against methicillin-resistant Staphylococcus aureus.
Hu, X; Jiang, J; Li, X; Lu, X; Lu, Y; Ren, Z; Yang, X; You, X; Zhao, L, 2013
)
0.83

Bioavailability

ExcerptReferenceRelevance
" The mean systemic bioavailability of netilmicin and vancomycin following a single intramuscular administration in normal chickens was 27."( Pharmacokinetics and tissue residues of netilmicin and vancomycin in chickens.
el-Komy, AA; el-Sayed, MG; el-Shiakh, LR, 1997
)
0.84
" In vivo bioavailability studies conducted with PHEA-PEG-C(16) micelles loaded with dexamethasone alcohol, confirmed that this system also provides a drug bioavailability greater in comparison with that obtained with water suspension of the same drug after ocular administration to rabbits."( Polyhydroxyethylaspartamide-based micelles for ocular drug delivery.
Cavallaro, G; Civiale, C; Giammona, G; Licciardi, M; Mazzone, MG, 2009
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Netilmicin, gentamicin, tobramycin, amikacin, kanamycin, streptomycin, and sisomicin were then given to groups of rats at three dosage levels corresponding to 10, 15 or 25 times the recommended human dose on a weight basis daily for 15 days. The obtained results indicated that the use of the dosing schedule of netilmic in with the dose intervals of 48 h in premature neonates should guarantee adequate peak and trough levels.

ExcerptRelevanceReference
" Despite a uniform dosing protocol, a wide range of netilmicin serum levels was obtained."( Clinical evaluation of netilmicin therapy in serious infections.
Fu, KP; Jahre, JA; Neu, HC, 1979
)
0.82
"A clinical trial involving forty hospitalized patients with urinary tract infections was conducted to compare the effectiveness and tolerance of four dosage regimens of netilmicin: 1, 2, 3, and 4 mg/kg administered twice daily for 7 or 8 days."( Comparison of multiple-dose regimens of netilmicin in patients with urinary tract infections.
Cox, CE, 1979
)
0.72
" The data indicate that on repetitive dosing the amount of drug in the body would be considerably underestimated if the prolonged terminal elimination phase were not taken into account."( Multicompartment pharmacokinetics of netilmicin.
Follath, F; Spring, P; Vozeh, S; Wenk, M, 1979
)
0.53
" In spite of approximately identical serum concentration curves and in vitro activity, especially the low dosage of netilmicin led to more favourable therapeutic results than equal doses of tobramycin."( [Netilmicin and tobramycin: comparative evaluation of pharmacokinetics, nephrotoxicity, and therapeutic efficacy in animal studies (author's transl)].
Abraham, M; Freiesleben, H; Marre, R; Sack, K, 1979
)
1.38
" A clinically useful correlation indicates that the half-life may be approximated as 3 times the serum creatinine concentration and may be used for adjustment of dosage of netilmicin in the treatment of patients with impaired renal function."( Pharmacokinetics of netilmicin in renal insufficiency and haemodialysis.
Dugal, R; Pechere, JC; Pechere, MM,
)
0.65
" These results support the idea that the major significance of the PAE is in its application to dosing regimens."( In vivo postantibiotic effect of isepamicin and other aminoglycosides in a thigh infection model in neutropenic mice.
Caminero, MM; Fuentes Martinez, F; Izquierdo Izquierdo, J; Minguez Minguez, F; Prieto Prieto, J, 1992
)
0.28
" Once-daily dosing of aminoglycosides results in higher peak plasma concentrations without increasing toxic reactions and with optimization of pharmacodynamic properties."( Penetration of netilmicin in the lower respiratory tract after once-daily dosing.
Colardyn, FA; Pauwels, RA; Valcke, YJ; Vogelaers, DP, 1992
)
0.64
" Human data suggest that once daily aminoglycoside dosing regimens are as effective as multiple dosing regimens."( Once daily aminoglycoside dosing: maintained efficacy with reduced nephrotoxicity?
Ariano, RE; Zhanel, GG, 1992
)
0.28
"Human pharmacokinetics of netilmicin during multiple dosing were studied in serum and in the fluid of skin blisters with two different ratios of interface area to fluid volume."( Interface-area-to-volume ratio of interstitial fluid in humans determined by pharmacokinetic analysis of netilmicin in small and large skin blisters.
Blaser, J; Lüthy, R; Rieder, HL, 1991
)
0.8
" This enabled us to derive dosage recommendations that result in peak and average concentrations within the desired range for 95% of the neonates with gestational age above 31 weeks, thus avoiding the need for individual drug-level monitoring in a well-defined large group of patients."( Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations.
Fattinger, K; Follath, F; Olafsson, A; Vlcek, J; Vozeh, S; Wenk, M, 1991
)
1.72
" In conclusion, these very sensitive tests of nephro- and oto-toxicity suggest that od dosing of amikacin or netilmicin is, if anything, safer than bd or tid dosing."( Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin.
Tulkens, PM, 1991
)
0.71
" It persisted longer than classical PAE but, even after continuous exposure, was not enough to suggest a loss of kill with a twice daily dosing regimen of netilmicin or ciprofloxacin."( Ionic binding, adaptive resistance and post-antibiotic effect of netilmicin and ciprofloxacin.
Gould, IM; Harvey, G; Jason, C; Milne, K, 1991
)
0.72
" Each twofold increase in dosage reduced the number of surviving bacteria fivefold."( First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use.
Daikos, GL; Jackson, GG; Lolans, VT, 1991
)
0.28
" Dosage schedules are proposed for netilmicin in patients with renal impairment."( Distribution kinetics of netilmicin in human blister fluid: effect of renal impairment.
Domínguez-Gil, A; Gómez, JR; Lanao, JM; López, A; Martin, J; Tabernero, JM, 1991
)
0.86
"In a retrospective study once-daily dosage of netilmicin was compared with the thrice-daily regimen in critically ill patients."( [Comparison of netilmicin administration once or three times daily in intensive care patients].
Frass, M; Graninger, W; Leithner, C; Podolsky, A; Traindl, O, 1991
)
0.89
" This was the first investigation of a once-daily dosing regimen conducted in seriously ill patients with systemic infections."( Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity?
Cronberg, S; Nordström, L; Ringberg, H; Tjernström, O; Walder, M, 1990
)
0.28
" The phenomenon has implications for effective initial dosing with aminoglycoside antibiotics."( The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing.
Daikos, GL; Jackson, GG; Lolans, VT, 1990
)
0.28
" However, the optimal dosing regimen of the aminoglycoside remains to be elucidated."( Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis.
Carbon, C; Fantin, B, 1990
)
0.52
" Microtiter checkerboard technique was compared with standard killing curve method and with killing curves obtained in kinetic in vitro models mimicking single or multiple dosing regimens according to human pharmacokinetics."( Interactions of antimicrobial combinations in vitro: the relativity of synergism.
Blaser, J, 1990
)
0.28
" Our findings are of particular importance for the interpretation of studies in small animals comparing different antimicrobial compounds or different dosage regimens."( Simulation of human pharmacokinetic profiles in mice, and impact on antimicrobial efficacy of netilmicin, ticarcillin and ceftazidime in the peritonitis-septicemia model.
Gerber, AU; Segessenmann, C; Stalder, B; Stritzko, T, 1990
)
0.5
" Ceftriaxone had the considerable practical advantages of once daily dosage without a need for blood monitoring."( Ceftriaxone vs. azlocillin and netilmicin in the treatment of febrile neutropenic children.
Smith, L; Stevens, RF; Will, AM; Williams, RF, 1990
)
0.57
"Once-daily dosing of aminoglycosides has been suggested to improve their efficacy and reduce their toxicity."( Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone.
Bouter, KP; de Vries, PJ; Dorrestein, GC; Nortier, JW; ter Braak, EW; van der Vegt, SG; van Dijk, A; Verbrugh, HA; Verkooyen, RP, 1990
)
0.48
"Patients randomized to either of the two dosing strategies were comparable regarding age, APACHE II score, concomitant diseases, infection site, and rate of culture-proven bacteremia."( Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone.
Bouter, KP; de Vries, PJ; Dorrestein, GC; Nortier, JW; ter Braak, EW; van der Vegt, SG; van Dijk, A; Verbrugh, HA; Verkooyen, RP, 1990
)
0.48
"Once-daily dosing of an aminoglycoside plus a long-acting cephalosporin in these patients constituted cost-effective and safe treatment for severe bacterial infections."( Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone.
Bouter, KP; de Vries, PJ; Dorrestein, GC; Nortier, JW; ter Braak, EW; van der Vegt, SG; van Dijk, A; Verbrugh, HA; Verkooyen, RP, 1990
)
0.48
"To complement a study on aminoglycoside dosing regimen and ototoxicity in the guinea pig, we designed an experiment to examine: (1) the effect of dosing regimen on guinea pig pharmacokinetic parameters, and (2) possible differential accumulation after repeated intramuscular administrations of netilmicin and amikacin (150 mg/kg/day) for 7 days by 1 or 3 daily injections."( Aminoglycoside dosing regimen and pharmacokinetic parameters in the guinea pig.
Bamonte, F; Dionisotti, S; Kramer, WG; Leung, P; Ongini, E, 1990
)
0.45
" Amikacin was also tested at 225 mg/kg/day with each dosing regimen."( Relation of dosing regimen to aminoglycoside ototoxicity: evaluation of auditory damage in the guinea pig.
Arpini, A; Bamonte, F; Dionisotti, S; Gamba, M; Melone, G; Ongini, E, 1990
)
0.28
" Although no adjustment in netilmicin dosing is required, tobramycin should be administered more frequently when given concomitantly with piperacillin to hemodialysis patients to avoid prolonged periods of subtherapeutic concentrations."( Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease.
Abraham, PA; Halstenson, CE; Heim-Duthoy, KL; Hirata, CA; Matzke, GR, 1990
)
0.81
" Netilmicin failed to affect either the vestibular or the acoustic apparatus in the animal groups receiving the two dosing regimens."( The impact of different dosing regimens of the aminoglycosides netilmicin and amikacin on vestibulotoxicity in the guinea pig.
Dionisotti, S; Draicchio, F; Errico, P; Ferraresi, A; Pettorossi, VE, 1990
)
1.43
"In 43 ICU patients undergoing continuous volume constant hemofiltration (CVHF), the pharmacokinetics of 12 drugs were investigated to ensure correct dosage adjustments."( [Dosage adjustment of drugs during continuous hemofiltration. Results and practical consequences of a prospective clinical study].
Dehne, M; el Abed, K; Hofmann, W; Kroh, U; Lennartz, H, 1989
)
0.28
" In some trials, the more easily implemented once daily administration of netilmicin has been as effective as multiple dosing regimens."( Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Campoli-Richards, DM; Chaplin, S; Goa, KL; Sayce, RH, 1989
)
1.95
" After six days of this dosage regiment, the peak and the valley concentrations are compared with those previously given by the computer as values at equilibrium."( [Adjusting the dosage of netilmicin from two measurements. Program validation].
Abgrall, JF; Dheilly, M; Guedes, Y; L'Azou, D; Le Garrec, J; Lebot, MA; Tanguy, RL; Voirin, T,
)
0.43
" In the framework of searching for preventive measures of aminoglycoside-induced nephrotoxicity, we investigated the influence of dosage regimen on the renal cortical accumulation of gentamicin and netilmicin in humans."( Once-daily dosing decreases renal accumulation of gentamicin and netilmicin.
De Broe, ME; Eestermans, G; Giuliano, RA; Verbist, L; Verpooten, GA, 1989
)
0.7
" A clinical useful correlation indicates that the half-life is approximately 3 times the serum creatinine concentration, and may be used for adjusting the netilmicin dosage in the treatment of patients with impaired renal function."( Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis.
Domingo, JV; García Díez, JM; Herrero, A; Mahiques, E; Rius Alarcó, F, 1988
)
0.8
" In conclusion, if it could be necessary to use habekacin and to prefer this aminoglycoside to gentamicin from an antibacterial activity point of view it is necessary to keep in mind that this drug is potentially nephrotoxic and that the dosage had to be strictly respected."( [Habekacin: a new aminoglycoside. Study of nephrotoxicity in rats in comparison with gentamicin, netilmicin and amikacin].
Fillastre, JP; Morin, JP; Olier, B; Thomas, N, 1988
)
0.49
" The highly dosed antibiotics were well tolerated and emergence of resistance was rarely observed."( Antimicrobial therapy of Pseudomonas pulmonary exacerbations in cystic fibrosis. A prospective evaluation of netilmicin plus azlocillin versus netilmicin plus ticarcillin.
Desgrandchamps, D; Kraemer, R; Schaad, UB, 1986
)
0.48
"This article reviews the clinical pharmacokinetics, clinical toxicity and cost-effectiveness analysis of aminoglycosides and of dosing services for aminoglycosides."( Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services.
Bailie, GR; Mathews, A, 1987
)
0.27
" Had parameters obtained from 2 points been used, mean dosage would have been underestimated by 15% for ceftazidime and 11% for netilmicin, and some patients would have received only 65% of the dose calculated from all available points."( Ethics of drug studies in infants: how many samples are required for accurate estimation of pharmacokinetic parameters in neonates?
James, A; Koren, G; Long, D, 1987
)
0.48
" After G and N, the creatinine clearance of the neonates was decreased according to the dosage given to the mother."( In utero aminoglycosides-induced nephrotoxicity in rat neonates.
Billerey, C; Coulon, G; Faucourt, A; Mallié, JP; Morin, JP, 1988
)
0.27
" The effect of such dosing on bacterial time-kill curves and on survival was compared with the effect of identical amounts of drug given as a single-bolus injection."( Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics.
Brugger, HP; Feller, C; Gerber, AU; Stalder, B; Stritzko, T, 1986
)
0.27
" Endotracheal administration of aminoglycosides has been advocated but the optimal dosage remains to be determined."( [Serum and bronchial concentrations of netilmicin during its continuous intratracheal administration].
Aguilera, D; Carrère-Debat, D; Coupry, A; Giudicelli, DP; Gontier, D; Holzapfel, L; Karlin, P, 1986
)
0.54
" If dosage of netilmicin is closely monitored by measuring serum concentrations, toxicity is minimal."( A prospective randomised comparison of cefotaxime vs. netilmicin vs. cefotaxime plus netilmicin in the treatment of hospitalised patients with serious sepsis.
Nazareth, B; Noone, P; Sage, R, 1987
)
0.88
" Since drug uptake kinetics determine the extent of cortical concentrations achieved, dosing strategies may affect cortical accumulation of aminoglycosides."( Choice of drug and dosage regimen. Two important risk factors for aminoglycoside nephrotoxicity.
De Broe, ME; Giuliano, RA; Verpooten, GA, 1986
)
0.27
"Several aminoglycoside dosage regimens were studied in a kinetic in vitro model."( Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model.
Blaser, J; Stone, BB; Zinner, SH, 1985
)
0.51
" Hematologic, serum chemical, and drug-serum (24-hr postdose) assays were performed at approximate monthly intervals during the dosing period."( Comparative ototoxicity of netilmicin, gentamicin, and tobramycin in cats.
McCormick, GC; Schwartz, E; Szot, RJ; Weinberg, E, 1985
)
0.57
" The implications of this study are: a different dosage adjustment of aminoglycosides is needed for patients routinely treated by HDF; HDF may be a very effective treatment for the overdose of many drugs."( Pharmacokinetics of netilmicin in hypertonic hemodiafiltration and standard hemodialysis.
Basile, C; Curino, E; Di Maggio, A; Scatizzi, A, 1985
)
0.59
" The experience of earlier investigations demonstrated the need for quantitative measurements and individual patient dosing which has reduced the risk of toxicity many fold."( The key role of aminoglycosides in antibacterial therapy and prophylaxis.
Jackson, GG, 1984
)
0.27
"The efficacy of various dosage schedules of netilmicin against Pseudomonas aeruginosa has been compared using an in vivo model (normal and granulocytopenic mice)."( [Bolus injection, short infusion or intravenous drip of aminoglycoside antibiotics? In vivo study with netilmicin and Pseudomonas aeruginosa].
Brugger, HP; Feller-Segessenmann, C; Gerber, AU, 1983
)
0.74
" Dose and dosage interval for each patient were determined by one-compartment pharmacokinetic analysis of six postinfusion netilmicin serum samples (0."( Clinical use of a one-compartment model for determining netilmicin pharmacokinetic parameters and dosage recommendations.
Crossley, KB; Rotschafer, JC; Russillo, NJ; Solem, LD; Strate, RG; Tofte, RW; Zaske, DE, 1983
)
0.72
"The value of netilmicin, like that of other antibiotics, is influenced by its antimicrobial specificity, dosage and ease of administration, activity in pus and the underlying condition of the host."( The clinical versatility of aminoglycosides.
Jackson, GG, 1984
)
0.64
"The plasma peak, trough, and peak-trough concentrations of netilmicin given to preterm and term infants were measured after different regimens to determine which dosage would provide satisfactory peak and trough concentrations."( Clinical pharmacology of netilmicin in the newborn.
Milner, RD; Phillips, AM, 1983
)
0.81
"The dosing frequency of aminoglycoside antibiotics may alter efficacy and toxicity independent of total daily dose."( Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin.
Bloxham, DD; Cash, HA; DiScenna, AO; Groden, DL; Grossniklaus, DA; Jacobs, MR; Klinger, JD; Luthe, MA; Powell, SH; Stern, RC; Thompson, WL, 1983
)
0.48
" When the dosage was adjusted according to the patient's weight and serum creatinine, some nephrotoxicity occurred, possibly due to drug accumulation."( Netilmicin treatment of complicated urinary tract infections.
Baumueller, A; Frimodt-Møller, N; Hoyme, U; Lau, C; Madsen, PO; Maigaard, S; Nielsen, OS; Welling, PG, 1980
)
1.7
" For patients with elevated plasma creatinine the dosage was reduced according to the degree of elevation."( Netilmicin therapy of patients with septicaemia and other severe infections.
Brandenhoff, P; Bretlau, P; Gammelgaard, PA; Jensen, SH; Rasmussen, F; Stafanger, G; Thomsen, VF, 1980
)
1.7
" The initial dosage of netilmicin was 200 mg twice a day (2."( Netilmicin 200 mg twice a day for adult patients with life-threatening infections. A preliminary report.
Amirak, ID; Noone, P; Perera, MR, 1980
)
2.01
" Netilmicin, gentamicin, tobramycin, amikacin, kanamycin, streptomycin, and sisomicin were then given to groups of rats at three dosage levels corresponding to 10, 15 or 25 times the recommended human dose on a weight basis daily for 15 days."( The nephrotoxic potential of netilmicin as determined in a rat model.
Luft, FC, 1980
)
1.46
" A standard regimen of 45 mg/kg/day with constant intravenous infusion and once daily dosing of each aminoglycoside was used, and in subsequent dogs netilmicin daily dose was increased to an average of 73 mg/kg/day."( Aminoglycoside nephrotoxicity in dogs: dependence on drug, dose and regimen.
Powell, S; Thompson, WL, 1980
)
0.46
" Although intermittent injections can result in higher levels of aminoglycosides within the bronchial secretions, such levels cannot be maintained for prolonged periods unless the dosage is increased."( Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of bronchopulmonary infections due to gram-negative bacteria.
Klastersky, J; Mombelli, G; Thys, JP,
)
0.13
"The efficacy and tolerance of netilmicin administered in a simplified dosage schedule (150 mg BID) were evaluated in an open study of 20 patients with acute systemic infections."( An evaluation of netilmicin, 150 mg BID, in systemic infections.
Kosuta, D; Kropec, I; Tambic, T, 1981
)
0.89
" The decrease of food intake at the dosage of 50 mg/kg and more, and the resultant depression of maternal body weight gain at the dosage of 100 mg/kg were observed in dams receiving NTL."( [Reproduction study on netilmicin. (1) Teratological study in rats (author's transl)].
Furuhashi, T; Komuro, E; Miyoshi, K; Nakayoshi, H; Nomura, A; Uehara, M, 1982
)
0.57
"Pharmacokinetics of netilmicin (NTL), a new aminoglycoside antibiotic, injected intramuscularly to Beagle dogs were compared with those of gentamicin (GM), and the relationship between NTL dosage administered and plasma level and urinary excretion was examined."( [Absorption, excretion and metabolism of netilmicin in beagle dogs (author's transl)].
Ohashi, H; Tokiwa, T, 1982
)
0.85
" The results indicate that twice daily dosage with 150 mg intramuscularly, either alone or in combination with other antibiotic therapy, was highly effective."( The use of netilmicin in a district general hospital.
Mummery, RV, 1982
)
0.65
" Dosage schedules based on pharmacokinetics are proposed for gestationally premature babies, mature newborns, and older children."( Pharmacokinetic assessment of netilmicin in newborns and older children.
Bergan, T; Michalsen, H, 1982
)
0.55
" In contrast to previous recommendations, but relying on well known pharmacokinetic data which show prolonged urinary excretion of aminoglycosides, netilmicin was administered according to the following dosage schedule: Intramuscular injections of 3 mg/kg in cases where renal function was unimpaired, and of 2 mg/kg where it was reduced, were administered at dosage intervals of 1 to 4 days."( [Netilmicin in refractory urinary tract infections. Good therapeutic effect in spite of long dosage intervals].
Brunner, FP; Follath, F; Mauracher, E; Thiel, G; Wenk, M, 1982
)
1.37
" The slope of the graph for netilmicin was distinctively flat; a comparatively flat dose-response curve for netilmicin has been reported also from in vivo studies of nephrotoxicity."( Studies of a potential in vitro test for estimation of toxicity of aminoglycoside antibiotics and polyamines.
Gonda, I; Harpur, ES; Kayes, JB; Langford, PR, 1982
)
0.56
" Some high-dose studies in rats have also suggested that the slope of the nephrotoxicity dose-response curve of netilmicin was less steep than the slopes of other aminoglycosides."( Nonparallel nephrotoxicity dose-response curves of aminoglycosides.
Barnett, D; Christensen, EF; Gordon, LL; Hottendorf, GH; Madissoo, H, 1981
)
0.47
" From a pharmacokinetic point of view, the dosage of netilmicin required may be the same in CF as in non-CF patients."( Pharmacokinetics of netilmicin in children with and without cystic fibrosis.
Bergan, T; Michalsen, H, 1981
)
0.84
" Elimination of netilmicin was prolonged in newborn infants with renal failure and requires dosage adjustment."( Netilmicin use in pediatric patients.
Chindasilpa, V; Hamilton, LR; Riff, LJ; Schauf, V, 1980
)
2.05
"Little has been reported on serum levels attained using once-daily aminoglycoside regimens and their relation to dosage administered and renal function."( Easier monitoring of aminoglycoside therapy with once-daily dosing schedules.
Büller, HR; Koopmans, RP; Kuijper, EJ; Prins, JM; Speelman, P, 1995
)
0.29
" Thus, monitoring of serum creatinine and aminoglycoside levels is recommended, especially for those with renal failure, in order to maintain an optimal dosage between toxic and noneffective serum aminoglycoside levels."( Pharmacokinetics of amikacin, netilmicin and tobramycin in children with chronic renal failure.
Emre, S; Eti, S; Nayir, A; Sirin, A; Yeşilbek, T,
)
0.42
" Individualized drug dosage regimens have made such therapy possible even in patients with impaired renal function."( Computation of drug concentrations in endocardial vegetations in patients during antibiotic therapy.
Barbaut, X; Brazier, JL; Chuzeville, M; Confesson, MA; el Brouzi, M; Ivanoff, N; Jelliffe, RW; Maire, P; Pivot, C; Vergnaud, JM, 1994
)
0.29
"To examine a once daily dosing regimen of netilmicin in critically ill neonates and children."( Once daily dosing of netilmicin in neonatal and pediatric intensive care.
Pfenninger, J; Wagner, BP, 1994
)
0.87
" (with dosage reduction in case of renal dysfunction)."( Once-daily gentamicin versus once-daily netilmicin in patients with serious infections--a randomized clinical trial.
Büller, HR; Kuijper, EJ; Prins, JM; Speelman, P; Tange, RA, 1994
)
0.56
"A once-daily dosing regimen for aminoglycosides is less expensive, at least as effective and possibly less toxic than multiple-daily dosing regimens."( Monitoring serum concentrations for once-daily netilmicin dosing regimens.
Blaser, J; König, C; Simmen, HP; Thurnheer, U, 1994
)
0.55
" It may be important to take account of the PAE when designing dosing regimens."( Postantibiotic effect of aminoglycosides on staphylococci.
Isaksson, B; Maller, R; Nilsson, LE; Nilsson, M, 1993
)
0.29
" These experimental data might provide a rationale for clinical trials of a once-a-day dosing regimen in the treatment of streptococcal but nonenterococcal endocarditis."( Simulated human serum profiles of one daily dose of ceftriaxone plus netilmicin in treatment of experimental streptococcal endocarditis.
Blatter, M; Entenza, J; Fluckiger, U; Francioli, P; Glauser, MP, 1993
)
0.52
" A meta-analysis of the published pharmacokinetic data is required to build up a knowledge-based computer system for dosage adjustment in renal failure."( Nonparametric meta-analysis of published data on kidney-function dependence of pharmacokinetic parameters for the aminoglycoside netilmicin.
Buettner, P; Erdmann, K; Giehl, M; Keller, F, 1993
)
0.49
" The virtual peak levels which had been determined by pharmacokinetic dosage calculation were compared with the serum concentrations obtained directly after the administration as well as after 15, 30, 60 and 180 min."( Studies on drug monitoring in thrice and once daily treatment with aminoglycosides.
Georgieff, M; Konrad, F; Neumeister, B; Rommel, H; Wagner, R, 1993
)
0.29
" During od dosing the trough level was extremely important in drug monitoring, whereas determination of the high peak level was of doubtful value."( Studies on drug monitoring in thrice and once daily treatment with aminoglycosides.
Georgieff, M; Konrad, F; Neumeister, B; Rommel, H; Wagner, R, 1993
)
0.29
" The results suggest that CRO-NET should be an effective combination for treating streptococcal endocarditis in humans and may permit a shorter duration of treatment and once-a-day dosing to be used."( Synergistic activity of ceftriaxone combined with netilmicin administered once daily for treatment of experimental streptococcal endocarditis.
Francioli, PB; Glauser, MP, 1993
)
0.54
"In a prospective, randomized trial, netilmicin given once daily (OD) was compared in terms of efficacy and safety with the conventional 8-hourly dosing regimen (TD), both in combination with a broad spectrum beta-lactam, as initial empirical therapy for febrile neutropenic patients; the total daily dosage of netilmicin in each group was 6 mg/kg body weight."( Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients.
Gaus, W; Kern, WV; Kurrle, E; Moritz, T; Reichle, A; Rozdzinski, E; Schmeiser, T, 1993
)
0.83
" Netilmicin was given to two additional groups at a higher dosage (6 mg/kg every 24 h intramuscularly) alone or in combination with vancomycin (15 mg/kg BID intravenously) for 12 days."( Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis.
Donta, I; Giamarellou, H; Karayiannakos, P; Pefanis, A; Perdikaris, G, 1995
)
1.49
"The effect of dosing regimen on nephrotoxicity, high frequency ototoxicity, efficacy and serum kinetics was studied in a prospective, randomised clinical study."( Nephrotoxicity, high frequency ototoxicity, efficacy and serum kinetics of once versus thrice daily dosing of netilmicin in patients with serious infections.
Blaser, J; König, C; Lüthy, R; Simmen, HP; Thurnheer, U, 1995
)
0.5
"In the past few decades aminoglycosides have usually been administered as multiple daily dosing regimens."( [Dosing aminoglycosides once a day].
Blaser, J, 1996
)
0.29
" However, the most favorable aminoglycoside dosing regimen for treating enterococcal endocarditis remains controversial."( Once-versus thrice-daily netilmicin combined with amoxicillin, penicillin, or vancomycin against Enterococcus faecalis in a pharmacodynamic in vitro model.
Blaser, J; Schwank, S, 1996
)
0.6
"Single daily dosage of netilmicin is generally accepted in systemic infections, due to biphasic bactericidal activity and prolonged postantibiotic effect of aminoglycosides."( Pharmacokinetics and bactericidal activity of a single daily dose of netilmicin in the treatment of CAPD-associated peritonitis.
Anding, K; Böhler, J; Krumme, B; Pelz, K; Schollmeyer, P, 1996
)
0.84
" Renal dysfunction is significantly more frequent in cirrhotic patients treated with netilmicin but with careful attention to dosage and fluid management the clinical effect is likely to be relatively modest."( A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients.
Burroughs, AK; Chin, JK; Greenslade, L; Kibbler, CC; McCormick, PA; McIntyre, N, 1997
)
0.77
"The potential nephrotoxicity and pharmacokinetic parameters of netilmicin were investigated in rabbits after single and multiple dosage regimens (7 mg/kg/12 h) allometrically equivalent to a once-daily regimen of 5 mg/kg/24 h in man."( Study on pharmacokinetics and nephrotoxicity of netilmicin in rabbits using a new dosage regimen.
Arévalo, M; Colino, CI; Domínguez-Gil, A; Lanao, JM; López, FG; Navarro, AS; Santos, M,
)
0.63
" The drugs concentrations during multiple dosage regimens were significantly increased in 2nd, 3rd, 4th and 5th days in comparison to the 1st day."( Pharmacokinetics and tissue residues of netilmicin and vancomycin in chickens.
el-Komy, AA; el-Sayed, MG; el-Shiakh, LR, 1997
)
0.56
" The patients were randomized into four groups: Group 1 received a single daily dose of netilmicin based upon weight, age and renal function according to a dosage nomogram [13] (mean dose 298 +/- 29 mg, median 300 mg, range 250-350 mg), group 2 received 150% of this standard dose (mean 418 +/- 45 mg, median 400 mg, range 350-500 mg), group 3 200% (mean 525 +/- 41 mg, median 500 mg, range 400-550 mg) and group 4 250% (mean 710 +/- 39 mg, median 650 mg, range 600-750 mg)."( Renal tolerability of four different once-daily dose regimen of netilmicin in critical care patients.
Burgmann, H; Frass, M; Graninger, W; Hollenstein, U; Knapp, S; Kofler, J; Laczika, K; Locker, GJ; Presterl, E; Staudinger, T; Stoiser, B; Winter, W, 1997
)
0.76
"The pharmacokinetic interaction of Netilmicin and Piperacillin has been studied as well as the potential protective effect that Piperacillin exert on nephrotoxicity caused by Netilmicin, when both antibiotics are administered to rabbits by single and multiple dosage regimens."( Pharmacokinetic parameters of netilmicin and protective effect of piperacillin regarding nephrotoxicity caused by netilmicin.
Arévalo, M; Lanao, JM; López, FG; Sánchez Navarro, A; Santos Navarro, M; Zarzuelo Castañeda, A,
)
0.7
" Numerous in-vitro and animal experiments and several clinical trials favour a once-daily dosage regimen of aminoglycosides, which provides a more rapid concentration-dependent bacterial killing and is probably less toxic than two or three dosage regimens."( [Once-daily dosage of aminoglycosides--a therapeutic simplification and an economical benefit].
Berild, D; Digranes, A; Sjursen, H, 1999
)
0.3
" Cumulative drug dose-response curves were obtained for three different muscles in 24 rabbits."( Neuromuscular blocking effects of the aminoglycoside antibiotics arbekacin, astromicin, isepamicin and netilmicin on the diaphragm and limb muscles in the rabbit.
Hashimoto, Y; Kato, M; Liu, M, 2001
)
0.53
" The validation of this technique as adapted to the Dimension RXL HM has allowed its use for routine dosage adjustment of amikacin and netilmicin."( [Evaluation of Emit netilmicin and amikacin assays on Dimension RXL HM (Dade Behring) open channels].
Baltassat, P; Berny, C; Manchon, M; Mialon, A; Vételé, F,
)
0.65
" Our goal was to develop a simplified dosage regimen for preterm infants which would result in therapeutic maximum serum concentrations early in the course of therapy."( Evaluation of a netilmicin-loading dose in very low birthweight infants.
Berger, A; Gludovatz, P; Kohlhauser, C; Kretzer, V; Prusa, AR; Rohrmeister, K, 2003
)
0.66
" A given single dose results in large variability in plasma concentrations and thus the population covariate final model can be used for direct estimation of initial dosing in patients."( Population pharmacokinetics of netilmicin in short-term prophylactic treatment.
Astobieta, A; Calvo, R; Jauregizar, N; Lukas, JC; Rodriguez Sasiain, JM; Wald, JA, 2003
)
0.6
"Our goal was to perform a pharmacokinetic analysis of netilmicin to develop the optimum dosage regimen of this antibiotic in premature neonates hospitalized in Neonate Intensive Care Unit of the Institute of Mother and Child in Warsaw."( [Pharmacokinetics of netilmicin in neonates].
Kaminska, E; Piekarczyk, A; Poszwinska, B; Rutkowska, M; Sosonowska, K; Taljanski, W,
)
0.7
" netilmicin every 24 h, then the dosing interval for the safety reasons was prolonged to 48 h in the premature group."( [Pharmacokinetics of netilmicin in neonates].
Kaminska, E; Piekarczyk, A; Poszwinska, B; Rutkowska, M; Sosonowska, K; Taljanski, W,
)
1.36
" The obtained results indicated that the use of the dosing schedule of netilmicin with the dose intervals of 48 h in premature neonates should guarantee adequate peak and trough levels without the need of routine monitoring of each patient in the premature neonate group except the very low weight neonates."( [Pharmacokinetics of netilmicin in neonates].
Kaminska, E; Piekarczyk, A; Poszwinska, B; Rutkowska, M; Sosonowska, K; Taljanski, W,
)
0.68
"Once-daily administration of aminoglycoside antibiotics has become the most acceptable dosing schedule for the majority of patients."( Use of once-daily netilmicin to treat infants with suspected sepsis in a neonatal intensive care unit.
Brooks, JR; Marlow, N; Millar, MR; Reeves, BC, 2004
)
0.66
"The aim of this study was to validate a simplified high-dosage, extended-interval netilmicin dosage regimen for infants."( Validation of a simplified netilmicin dosage regimen in infants.
Flaegstad, T; Klingenberg, C; Lier, T; Småbrekke, L, 2004
)
0.85
" Increased volumes of distribution can be estimated by the bioimpedance measurements but are not associated with requirements for higher dosage of the glycopeptide or aminoglycoside antibiotics."( Can bioimpedance determine the volume of distribution of antibiotics in sepsis?
Balik, M; Kolar, M; Pachl, J; Sedivy, J; Smejkalova, V; Waldauf, P, 2005
)
0.33
" A number of neonates did not reach targeted peak and trough netilmicin serum concentrations, suggesting that a higher loading dose and a prolonged dosing interval might enhance the effectiveness and safety of netilmicin in preterm neonates immediately after birth."( Pharmacokinetics of a netilmicin loading dose on the first postnatal day in preterm neonates with very low gestational age.
Beedgen, B; Haefeli, WE; Linderkamp, O; Mikus, G; Rengelshausen, J; Tsamouranis, K; Walter-Sack, I, 2006
)
0.89
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" In our study once-daily dosing schedule shows similar low rates of nephrotoxicity, compared with multiple daily dosing schedule: this result may support the general adoption of once-daily dosing of netilmicin in clinical practice."( Use of netilmicin once or twice daily in preterm newborns: evaluation of nephrotoxicity by urinary alpha1-microglobulin and retinol binding protein.
Alessi, D; Appino, I; Cirina, P; Coscia, A; Fabris, C; Maiorca, D; Martano, C; Rossi, C, 2008
)
0.99
"The aim of this study was develop an optimal dosing regimen for netilmicin in neonates."( Individualising netilmicin dosing in neonates.
Broadbent, RS; Medlicott, NJ; Reith, DM; Sherwin, CM, 2008
)
0.93
" The model was used to simulate dosing regimens."( Individualising netilmicin dosing in neonates.
Broadbent, RS; Medlicott, NJ; Reith, DM; Sherwin, CM, 2008
)
0.69
" The optimal dosing was 5 mg/kg ever 36 h, 5 mg/kg every 24 h, 6 mg/kg every 24 h and 7 mg/kg every 24 h for neonates < or =27, 28-30, 31-33 and > or =34 weeks PMA, respectively."( Individualising netilmicin dosing in neonates.
Broadbent, RS; Medlicott, NJ; Reith, DM; Sherwin, CM, 2008
)
0.69
"Individualisation of netilmicin dosing in neonates requires adjustment of dose by body weight, and dosing interval by both PMA and CWT."( Individualising netilmicin dosing in neonates.
Broadbent, RS; Medlicott, NJ; Reith, DM; Sherwin, CM, 2008
)
1.01
" Cl and t(1/2) are influenced by development, and this must be taken into consideration when planning a dosage regimen with aminoglycosides in the neonate."( Clinical pharmacokinetics of aminoglycosides in the neonate: a review.
Pacifici, GM, 2009
)
0.35
"4-41 weeks) treated with netilmicin (4-5 mg/kg in extended dosing intervals) for postnatal sepsis in the first week of life received either fluid therapy or parenteral nutrition."( Netilmicin in the neonate: pharmacokinetic analysis and influence of parenteral nutrition.
Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009
)
2.1
"Provision of parenteral nutrition (versus fluid therapy) in critically ill neonates >32 weeks did not significantly affect netilmicin pharmacokinetics and therefore does not require modification of recommended netilmicin dosage regimens."( Netilmicin in the neonate: pharmacokinetic analysis and influence of parenteral nutrition.
Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009
)
2
"The aim of this study was to optimalise netilmicin dosage in low and very low birthweight premature neonates, based on drug serum concentrations obtained during therapeutic drug monitoring (TDM)."( [Optimalisation of netilmicin dosage based on therapeutic drug monitoring during the first days of life in very preterm neonates (gestational age 23-32 weeks)].
Kamińska, E; Nowakowska-Szyrwińska, E; Nowicka, K; Piekarczyk, A; Polak, K; Rutkowska, M; Szamotulska, K,
)
0.73
" Due to excessive trough levels, the dosing regimen was modified, prolonging the interval between doses to 48 hours."( [Optimalisation of netilmicin dosage based on therapeutic drug monitoring during the first days of life in very preterm neonates (gestational age 23-32 weeks)].
Kamińska, E; Nowakowska-Szyrwińska, E; Nowicka, K; Piekarczyk, A; Polak, K; Rutkowska, M; Szamotulska, K,
)
0.46
"The results indicate that netilmicin dosage of 6 mg/kg every 48 h can ensure the desired trough and peak levels in premature neonates without the necessity of routine monitoring of antibiotic concentration."( [Optimalisation of netilmicin dosage based on therapeutic drug monitoring during the first days of life in very preterm neonates (gestational age 23-32 weeks)].
Kamińska, E; Nowakowska-Szyrwińska, E; Nowicka, K; Piekarczyk, A; Polak, K; Rutkowska, M; Szamotulska, K,
)
0.76
" However, the optimal aminoglycoside or the optimal dosage remains uncertain."( The optimal aminoglycoside and its dosage for the treatment of severe Enterococcus faecalis infection. An experimental study in the rabbit endocarditis model.
Asseray, N; Bugnon, D; Caillon, J; Dubé, L; Jacqueline, C; Potel, G, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (58)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.37580.006038.004119,952.5996AID1159521
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.01390.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
30S ribosomal protein S6Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S7Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L15Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L10Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L11Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L7/L12Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L19Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L1Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L20Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L27Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L28Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L29Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L31Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L31 type BEscherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L32Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L33Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L34Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L35Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L36Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S10Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S11Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S12Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S13Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S16Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S18Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S19Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S20Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S2Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S3Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S4Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S5Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S8Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S9Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L13Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L14Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L16Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L23Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S15Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L17Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L21Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L30Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L6Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S14Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S17Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S1Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L18Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L2Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L3Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L24Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L4Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L22Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L5Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
30S ribosomal protein S21Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L25Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
50S ribosomal protein L36 2Escherichia coli K-12IC50 (µMol)0.02000.00891.20355.0000AID1575870
Tyrosyl-DNA phosphodiesterase 1Homo sapiens (human)IC50 (µMol)8,000.00000.01203.32138.4300AID1631084
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (40)

Processvia Protein(s)Taxonomy
cytoplasmic translation30S ribosomal protein S6Escherichia coli K-12
translation30S ribosomal protein S6Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S7Escherichia coli K-12
negative regulation of translation30S ribosomal protein S7Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S7Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S7Escherichia coli K-12
translation30S ribosomal protein S7Escherichia coli K-12
negative regulation of translation30S ribosomal protein S7Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L15Escherichia coli K-12
translation50S ribosomal protein L15Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L10Escherichia coli K-12
translation50S ribosomal protein L10Escherichia coli K-12
regulation of translation50S ribosomal protein L10Escherichia coli K-12
negative regulation of translation50S ribosomal protein L10Escherichia coli K-12
translation50S ribosomal protein L11Escherichia coli K-12
translational termination50S ribosomal protein L11Escherichia coli K-12
stringent response50S ribosomal protein L11Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L11Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L11Escherichia coli K-12
translation50S ribosomal protein L11Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L7/L12Escherichia coli K-12
translation50S ribosomal protein L7/L12Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L19Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L19Escherichia coli K-12
translation50S ribosomal protein L19Escherichia coli K-12
negative regulation of translational initiation50S ribosomal protein L1Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L1Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L1Escherichia coli K-12
translation50S ribosomal protein L1Escherichia coli K-12
regulation of translation50S ribosomal protein L1Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L20Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L20Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L20Escherichia coli K-12
translation50S ribosomal protein L20Escherichia coli K-12
negative regulation of translation50S ribosomal protein L20Escherichia coli K-12
cytosolic ribosome assembly50S ribosomal protein L27Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L27Escherichia coli K-12
regulation of cell growth50S ribosomal protein L27Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L27Escherichia coli K-12
translation50S ribosomal protein L27Escherichia coli K-12
positive regulation of ribosome biogenesis50S ribosomal protein L27Escherichia coli K-12
assembly of large subunit precursor of preribosome50S ribosomal protein L27Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L28Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L28Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L28Escherichia coli K-12
translation50S ribosomal protein L28Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L29Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L29Escherichia coli K-12
translation50S ribosomal protein L29Escherichia coli K-12
translation50S ribosomal protein L31Escherichia coli K-12
translational initiation50S ribosomal protein L31Escherichia coli K-12
negative regulation of cytoplasmic translational initiation50S ribosomal protein L31Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L31Escherichia coli K-12
translation50S ribosomal protein L31Escherichia coli K-12
cellular response to zinc ion starvation50S ribosomal protein L31 type BEscherichia coli K-12
cytoplasmic translation50S ribosomal protein L31 type BEscherichia coli K-12
translation50S ribosomal protein L31 type BEscherichia coli K-12
response to reactive oxygen species50S ribosomal protein L32Escherichia coli K-12
response to radiation50S ribosomal protein L32Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L32Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L32Escherichia coli K-12
translation50S ribosomal protein L32Escherichia coli K-12
response to antibiotic50S ribosomal protein L33Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L33Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L33Escherichia coli K-12
translation50S ribosomal protein L33Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L34Escherichia coli K-12
translation50S ribosomal protein L34Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L35Escherichia coli K-12
translation50S ribosomal protein L35Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L36Escherichia coli K-12
translation50S ribosomal protein L36Escherichia coli K-12
transcription antitermination30S ribosomal protein S10Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S10Escherichia coli K-12
translation30S ribosomal protein S10Escherichia coli K-12
transcription antitermination30S ribosomal protein S10Escherichia coli K-12
regulation of DNA-templated transcription elongation30S ribosomal protein S10Escherichia coli K-12
ribosome biogenesis30S ribosomal protein S10Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S11Escherichia coli K-12
translation30S ribosomal protein S11Escherichia coli K-12
Group I intron splicing30S ribosomal protein S12Escherichia coli K-12
positive regulation of RNA splicing30S ribosomal protein S12Escherichia coli K-12
RNA folding30S ribosomal protein S12Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S12Escherichia coli K-12
translation30S ribosomal protein S12Escherichia coli K-12
response to antibiotic30S ribosomal protein S12Escherichia coli K-12
maintenance of translational fidelity30S ribosomal protein S12Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S13Escherichia coli K-12
translation30S ribosomal protein S13Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S16Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S16Escherichia coli K-12
DNA metabolic process30S ribosomal protein S16Escherichia coli K-12
translation30S ribosomal protein S16Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S18Escherichia coli K-12
translation30S ribosomal protein S18Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S19Escherichia coli K-12
translation30S ribosomal protein S19Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S19Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S20Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S20Escherichia coli K-12
translation30S ribosomal protein S20Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S2Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S2Escherichia coli K-12
translation30S ribosomal protein S2Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S3Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S3Escherichia coli K-12
translation30S ribosomal protein S3Escherichia coli K-12
transcription antitermination30S ribosomal protein S4Escherichia coli K-12
negative regulation of translational initiation30S ribosomal protein S4Escherichia coli K-12
maintenance of translational fidelity30S ribosomal protein S4Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S4Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S4Escherichia coli K-12
DNA-templated transcription termination30S ribosomal protein S4Escherichia coli K-12
translation30S ribosomal protein S4Escherichia coli K-12
regulation of translation30S ribosomal protein S4Escherichia coli K-12
transcription antitermination30S ribosomal protein S4Escherichia coli K-12
ribosome biogenesis30S ribosomal protein S4Escherichia coli K-12
response to antibiotic30S ribosomal protein S4Escherichia coli K-12
ribosomal small subunit biogenesis30S ribosomal protein S4Escherichia coli K-12
maintenance of translational fidelity30S ribosomal protein S5Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S5Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S5Escherichia coli K-12
translation30S ribosomal protein S5Escherichia coli K-12
response to antibiotic30S ribosomal protein S5Escherichia coli K-12
regulation of mRNA stability30S ribosomal protein S8Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S8Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S8Escherichia coli K-12
translation30S ribosomal protein S8Escherichia coli K-12
regulation of translation30S ribosomal protein S8Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S9Escherichia coli K-12
translation30S ribosomal protein S9Escherichia coli K-12
negative regulation of translation50S ribosomal protein L13Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L13Escherichia coli K-12
translation50S ribosomal protein L13Escherichia coli K-12
negative regulation of translation50S ribosomal protein L13Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L14Escherichia coli K-12
translation50S ribosomal protein L14Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L16Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L16Escherichia coli K-12
translation50S ribosomal protein L16Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L23Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L23Escherichia coli K-12
translation50S ribosomal protein L23Escherichia coli K-12
translation30S ribosomal protein S15Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S15Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S15Escherichia coli K-12
translation30S ribosomal protein S15Escherichia coli K-12
regulation of translation30S ribosomal protein S15Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L17Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L17Escherichia coli K-12
translation50S ribosomal protein L17Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L21Escherichia coli K-12
translation50S ribosomal protein L21Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L30Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L30Escherichia coli K-12
translation50S ribosomal protein L30Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L6Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L6Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L6Escherichia coli K-12
translation50S ribosomal protein L6Escherichia coli K-12
response to antibiotic50S ribosomal protein L6Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S14Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S14Escherichia coli K-12
translation30S ribosomal protein S14Escherichia coli K-12
response to antibiotic30S ribosomal protein S17Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S17Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S17Escherichia coli K-12
translation30S ribosomal protein S17Escherichia coli K-12
response to antibiotic30S ribosomal protein S17Escherichia coli K-12
translation30S ribosomal protein S1Escherichia coli K-12
RNA secondary structure unwinding30S ribosomal protein S1Escherichia coli K-12
negative regulation of cytoplasmic translation30S ribosomal protein S1Escherichia coli K-12
positive regulation of cytoplasmic translation30S ribosomal protein S1Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S1Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S1Escherichia coli K-12
translation30S ribosomal protein S1Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L18Escherichia coli K-12
translation50S ribosomal protein L18Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L2Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L2Escherichia coli K-12
translation50S ribosomal protein L2Escherichia coli K-12
negative regulation of DNA-templated DNA replication initiation50S ribosomal protein L2Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L3Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L3Escherichia coli K-12
translation50S ribosomal protein L3Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L24Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L24Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L24Escherichia coli K-12
translation50S ribosomal protein L24Escherichia coli K-12
transcriptional attenuation50S ribosomal protein L4Escherichia coli K-12
negative regulation of cytoplasmic translation50S ribosomal protein L4Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L4Escherichia coli K-12
DNA-templated transcription termination50S ribosomal protein L4Escherichia coli K-12
translation50S ribosomal protein L4Escherichia coli K-12
regulation of translation50S ribosomal protein L4Escherichia coli K-12
negative regulation of translation50S ribosomal protein L4Escherichia coli K-12
ribosome assembly50S ribosomal protein L4Escherichia coli K-12
negative regulation of DNA-templated transcription50S ribosomal protein L4Escherichia coli K-12
response to antibiotic50S ribosomal protein L4Escherichia coli K-12
translation50S ribosomal protein L22Escherichia coli K-12
cytosolic ribosome assembly50S ribosomal protein L22Escherichia coli K-12
assembly of large subunit precursor of preribosome50S ribosomal protein L22Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L22Escherichia coli K-12
translation50S ribosomal protein L22Escherichia coli K-12
ribosome assembly50S ribosomal protein L22Escherichia coli K-12
response to antibiotic50S ribosomal protein L22Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L5Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L5Escherichia coli K-12
translation50S ribosomal protein L5Escherichia coli K-12
ribosomal small subunit assembly30S ribosomal protein S21Escherichia coli K-12
cytoplasmic translation30S ribosomal protein S21Escherichia coli K-12
translation30S ribosomal protein S21Escherichia coli K-12
translation50S ribosomal protein L25Escherichia coli K-12
response to radiation50S ribosomal protein L25Escherichia coli K-12
negative regulation of translation50S ribosomal protein L25Escherichia coli K-12
ribosomal large subunit assembly50S ribosomal protein L25Escherichia coli K-12
cytoplasmic translation50S ribosomal protein L25Escherichia coli K-12
translation50S ribosomal protein L25Escherichia coli K-12
translation50S ribosomal protein L36 2Escherichia coli K-12
single strand break repairTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
DNA repairTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
double-strand break repairTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (33)

Processvia Protein(s)Taxonomy
structural constituent of ribosome30S ribosomal protein S6Escherichia coli K-12
protein binding30S ribosomal protein S6Escherichia coli K-12
rRNA binding30S ribosomal protein S6Escherichia coli K-12
mRNA 5'-UTR binding30S ribosomal protein S6Escherichia coli K-12
small ribosomal subunit rRNA binding30S ribosomal protein S6Escherichia coli K-12
tRNA binding30S ribosomal protein S7Escherichia coli K-12
RNA binding30S ribosomal protein S7Escherichia coli K-12
mRNA binding30S ribosomal protein S7Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S7Escherichia coli K-12
protein binding30S ribosomal protein S7Escherichia coli K-12
rRNA binding30S ribosomal protein S7Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L15Escherichia coli K-12
protein binding50S ribosomal protein L15Escherichia coli K-12
rRNA binding50S ribosomal protein L15Escherichia coli K-12
GTPase activity50S ribosomal protein L10Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L10Escherichia coli K-12
protein binding50S ribosomal protein L10Escherichia coli K-12
rRNA binding50S ribosomal protein L10Escherichia coli K-12
ribosome binding50S ribosomal protein L10Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L10Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L11Escherichia coli K-12
protein binding50S ribosomal protein L11Escherichia coli K-12
rRNA binding50S ribosomal protein L11Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L11Escherichia coli K-12
GTPase activity50S ribosomal protein L7/L12Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L7/L12Escherichia coli K-12
protein binding50S ribosomal protein L7/L12Escherichia coli K-12
protein homodimerization activity50S ribosomal protein L7/L12Escherichia coli K-12
ribosome binding50S ribosomal protein L7/L12Escherichia coli K-12
mRNA binding50S ribosomal protein L7/L12Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L19Escherichia coli K-12
rRNA binding50S ribosomal protein L19Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L19Escherichia coli K-12
tRNA binding50S ribosomal protein L1Escherichia coli K-12
RNA binding50S ribosomal protein L1Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L1Escherichia coli K-12
protein binding50S ribosomal protein L1Escherichia coli K-12
rRNA binding50S ribosomal protein L1Escherichia coli K-12
mRNA regulatory element binding translation repressor activity50S ribosomal protein L20Escherichia coli K-12
mRNA binding50S ribosomal protein L20Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L20Escherichia coli K-12
rRNA binding50S ribosomal protein L20Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L20Escherichia coli K-12
tRNA binding50S ribosomal protein L27Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L27Escherichia coli K-12
protein binding50S ribosomal protein L27Escherichia coli K-12
rRNA binding50S ribosomal protein L27Escherichia coli K-12
ribosome binding50S ribosomal protein L27Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L28Escherichia coli K-12
protein binding50S ribosomal protein L28Escherichia coli K-12
rRNA binding50S ribosomal protein L28Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L29Escherichia coli K-12
rRNA binding50S ribosomal protein L29Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L31Escherichia coli K-12
zinc ion binding50S ribosomal protein L31Escherichia coli K-12
rRNA binding50S ribosomal protein L31Escherichia coli K-12
metal ion binding50S ribosomal protein L31Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L31 type BEscherichia coli K-12
structural constituent of ribosome50S ribosomal protein L32Escherichia coli K-12
protein binding50S ribosomal protein L32Escherichia coli K-12
tRNA binding50S ribosomal protein L33Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L33Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L34Escherichia coli K-12
protein binding50S ribosomal protein L34Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L35Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L36Escherichia coli K-12
tRNA binding30S ribosomal protein S10Escherichia coli K-12
transcription antitermination factor activity, RNA binding30S ribosomal protein S10Escherichia coli K-12
RNA binding30S ribosomal protein S10Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S10Escherichia coli K-12
protein binding30S ribosomal protein S10Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S11Escherichia coli K-12
protein binding30S ribosomal protein S11Escherichia coli K-12
rRNA binding30S ribosomal protein S11Escherichia coli K-12
small ribosomal subunit rRNA binding30S ribosomal protein S11Escherichia coli K-12
tRNA binding30S ribosomal protein S12Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S12Escherichia coli K-12
protein binding30S ribosomal protein S12Escherichia coli K-12
rRNA binding30S ribosomal protein S12Escherichia coli K-12
misfolded RNA binding30S ribosomal protein S12Escherichia coli K-12
tRNA binding30S ribosomal protein S13Escherichia coli K-12
RNA binding30S ribosomal protein S13Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S13Escherichia coli K-12
protein binding30S ribosomal protein S13Escherichia coli K-12
rRNA binding30S ribosomal protein S13Escherichia coli K-12
four-way junction DNA binding30S ribosomal protein S16Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S16Escherichia coli K-12
endonuclease activity30S ribosomal protein S16Escherichia coli K-12
DNA endonuclease activity30S ribosomal protein S16Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S18Escherichia coli K-12
protein binding30S ribosomal protein S18Escherichia coli K-12
rRNA binding30S ribosomal protein S18Escherichia coli K-12
mRNA 5'-UTR binding30S ribosomal protein S18Escherichia coli K-12
small ribosomal subunit rRNA binding30S ribosomal protein S18Escherichia coli K-12
tRNA binding30S ribosomal protein S19Escherichia coli K-12
RNA binding30S ribosomal protein S19Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S19Escherichia coli K-12
rRNA binding30S ribosomal protein S19Escherichia coli K-12
RNA binding30S ribosomal protein S20Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S20Escherichia coli K-12
ornithine decarboxylase inhibitor activity30S ribosomal protein S20Escherichia coli K-12
rRNA binding30S ribosomal protein S20Escherichia coli K-12
small ribosomal subunit rRNA binding30S ribosomal protein S20Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S2Escherichia coli K-12
protein binding30S ribosomal protein S2Escherichia coli K-12
zinc ion binding30S ribosomal protein S2Escherichia coli K-12
RNA binding30S ribosomal protein S3Escherichia coli K-12
mRNA binding30S ribosomal protein S3Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S3Escherichia coli K-12
rRNA binding30S ribosomal protein S3Escherichia coli K-12
mRNA regulatory element binding translation repressor activity30S ribosomal protein S4Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S4Escherichia coli K-12
protein binding30S ribosomal protein S4Escherichia coli K-12
rRNA binding30S ribosomal protein S4Escherichia coli K-12
mRNA 5'-UTR binding30S ribosomal protein S4Escherichia coli K-12
RNA binding30S ribosomal protein S5Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S5Escherichia coli K-12
protein binding30S ribosomal protein S5Escherichia coli K-12
rRNA binding30S ribosomal protein S5Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S8Escherichia coli K-12
rRNA binding30S ribosomal protein S8Escherichia coli K-12
tRNA binding30S ribosomal protein S9Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S9Escherichia coli K-12
RNA binding30S ribosomal protein S9Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L13Escherichia coli K-12
zinc ion binding50S ribosomal protein L13Escherichia coli K-12
mRNA 5'-UTR binding50S ribosomal protein L13Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L13Escherichia coli K-12
mRNA binding50S ribosomal protein L13Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L14Escherichia coli K-12
protein binding50S ribosomal protein L14Escherichia coli K-12
rRNA binding50S ribosomal protein L14Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L14Escherichia coli K-12
tRNA binding50S ribosomal protein L16Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L16Escherichia coli K-12
rRNA binding50S ribosomal protein L16Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L23Escherichia coli K-12
protein binding50S ribosomal protein L23Escherichia coli K-12
rRNA binding50S ribosomal protein L23Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S15Escherichia coli K-12
rRNA binding30S ribosomal protein S15Escherichia coli K-12
small ribosomal subunit rRNA binding30S ribosomal protein S15Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L17Escherichia coli K-12
protein binding50S ribosomal protein L17Escherichia coli K-12
RNA binding50S ribosomal protein L21Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L21Escherichia coli K-12
rRNA binding50S ribosomal protein L21Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L30Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L6Escherichia coli K-12
rRNA binding50S ribosomal protein L6Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L6Escherichia coli K-12
tRNA binding30S ribosomal protein S14Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S14Escherichia coli K-12
rRNA binding30S ribosomal protein S14Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S17Escherichia coli K-12
zinc ion binding30S ribosomal protein S17Escherichia coli K-12
rRNA binding30S ribosomal protein S17Escherichia coli K-12
molecular adaptor activity30S ribosomal protein S17Escherichia coli K-12
small ribosomal subunit rRNA binding30S ribosomal protein S17Escherichia coli K-12
RNA binding30S ribosomal protein S1Escherichia coli K-12
single-stranded RNA binding30S ribosomal protein S1Escherichia coli K-12
mRNA binding30S ribosomal protein S1Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S1Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L18Escherichia coli K-12
5S rRNA binding50S ribosomal protein L18Escherichia coli K-12
rRNA binding50S ribosomal protein L18Escherichia coli K-12
RNA binding50S ribosomal protein L2Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L2Escherichia coli K-12
protein binding50S ribosomal protein L2Escherichia coli K-12
zinc ion binding50S ribosomal protein L2Escherichia coli K-12
transferase activity50S ribosomal protein L2Escherichia coli K-12
rRNA binding50S ribosomal protein L2Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L3Escherichia coli K-12
protein binding50S ribosomal protein L3Escherichia coli K-12
rRNA binding50S ribosomal protein L3Escherichia coli K-12
RNA binding50S ribosomal protein L24Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L24Escherichia coli K-12
protein binding50S ribosomal protein L24Escherichia coli K-12
rRNA binding50S ribosomal protein L24Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L24Escherichia coli K-12
RNA-binding transcription regulator activity50S ribosomal protein L4Escherichia coli K-12
DNA binding50S ribosomal protein L4Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L4Escherichia coli K-12
protein binding50S ribosomal protein L4Escherichia coli K-12
rRNA binding50S ribosomal protein L4Escherichia coli K-12
translation repressor activity50S ribosomal protein L4Escherichia coli K-12
mRNA 5'-UTR binding50S ribosomal protein L4Escherichia coli K-12
endoribonuclease inhibitor activity50S ribosomal protein L4Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L22Escherichia coli K-12
protein binding50S ribosomal protein L22Escherichia coli K-12
rRNA binding50S ribosomal protein L22Escherichia coli K-12
large ribosomal subunit rRNA binding50S ribosomal protein L22Escherichia coli K-12
tRNA binding50S ribosomal protein L5Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L5Escherichia coli K-12
5S rRNA binding50S ribosomal protein L5Escherichia coli K-12
rRNA binding50S ribosomal protein L5Escherichia coli K-12
RNA binding50S ribosomal protein L5Escherichia coli K-12
structural constituent of ribosome30S ribosomal protein S21Escherichia coli K-12
rRNA binding30S ribosomal protein S21Escherichia coli K-12
RNA binding50S ribosomal protein L25Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L25Escherichia coli K-12
5S rRNA binding50S ribosomal protein L25Escherichia coli K-12
rRNA binding50S ribosomal protein L25Escherichia coli K-12
structural constituent of ribosome50S ribosomal protein L36 2Escherichia coli K-12
double-stranded DNA bindingTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
single-stranded DNA bindingTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
exonuclease activityTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
protein bindingTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
3'-tyrosyl-DNA phosphodiesterase activityTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
cytoplasm30S ribosomal protein S6Escherichia coli K-12
cytosol30S ribosomal protein S6Escherichia coli K-12
ribosome30S ribosomal protein S6Escherichia coli K-12
intracellular organelle30S ribosomal protein S6Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S6Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S6Escherichia coli K-12
cytosol30S ribosomal protein S7Escherichia coli K-12
ribosome30S ribosomal protein S7Escherichia coli K-12
membrane30S ribosomal protein S7Escherichia coli K-12
cytoplasm30S ribosomal protein S7Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S7Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S7Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S7Escherichia coli K-12
ribosome30S ribosomal protein S7Escherichia coli K-12
ribosome50S ribosomal protein L15Escherichia coli K-12
cytoplasm50S ribosomal protein L15Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L15Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L15Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L15Escherichia coli K-12
cytosol50S ribosomal protein L10Escherichia coli K-12
ribosome50S ribosomal protein L10Escherichia coli K-12
cytoplasm50S ribosomal protein L10Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L10Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L10Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L10Escherichia coli K-12
cytosol50S ribosomal protein L11Escherichia coli K-12
ribosome50S ribosomal protein L11Escherichia coli K-12
cytoplasm50S ribosomal protein L11Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L11Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L11Escherichia coli K-12
cytoplasm50S ribosomal protein L7/L12Escherichia coli K-12
cytosol50S ribosomal protein L7/L12Escherichia coli K-12
ribosome50S ribosomal protein L7/L12Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L7/L12Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L7/L12Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L7/L12Escherichia coli K-12
cytosol50S ribosomal protein L19Escherichia coli K-12
ribosome50S ribosomal protein L19Escherichia coli K-12
cytoplasm50S ribosomal protein L19Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L19Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L19Escherichia coli K-12
cytosol50S ribosomal protein L1Escherichia coli K-12
ribosome50S ribosomal protein L1Escherichia coli K-12
cytoplasm50S ribosomal protein L1Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L1Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L1Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L1Escherichia coli K-12
cytosol50S ribosomal protein L20Escherichia coli K-12
ribosome50S ribosomal protein L20Escherichia coli K-12
cytoplasm50S ribosomal protein L20Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L20Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L20Escherichia coli K-12
ribosome50S ribosomal protein L27Escherichia coli K-12
cytoplasm50S ribosomal protein L27Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L27Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L27Escherichia coli K-12
cytosol50S ribosomal protein L28Escherichia coli K-12
ribosome50S ribosomal protein L28Escherichia coli K-12
cytoplasm50S ribosomal protein L28Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L28Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L28Escherichia coli K-12
ribosome50S ribosomal protein L29Escherichia coli K-12
cytoplasm50S ribosomal protein L29Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L29Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L29Escherichia coli K-12
cytosol50S ribosomal protein L31Escherichia coli K-12
ribosome50S ribosomal protein L31Escherichia coli K-12
cytoplasm50S ribosomal protein L31Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L31Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L31Escherichia coli K-12
ribosome50S ribosomal protein L31 type BEscherichia coli K-12
cytoplasm50S ribosomal protein L31 type BEscherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L31 type BEscherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L31 type BEscherichia coli K-12
cytosol50S ribosomal protein L32Escherichia coli K-12
ribosome50S ribosomal protein L32Escherichia coli K-12
cytoplasm50S ribosomal protein L32Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L32Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L32Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L32Escherichia coli K-12
cytoplasm50S ribosomal protein L33Escherichia coli K-12
cytosol50S ribosomal protein L33Escherichia coli K-12
ribosome50S ribosomal protein L33Escherichia coli K-12
intracellular organelle50S ribosomal protein L33Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L33Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L33Escherichia coli K-12
ribosome50S ribosomal protein L34Escherichia coli K-12
cytoplasm50S ribosomal protein L34Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L34Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L34Escherichia coli K-12
ribosome50S ribosomal protein L35Escherichia coli K-12
cytoplasm50S ribosomal protein L35Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L35Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L35Escherichia coli K-12
cytoplasm50S ribosomal protein L36Escherichia coli K-12
ribosome50S ribosomal protein L36Escherichia coli K-12
intracellular organelle50S ribosomal protein L36Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L36Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L36Escherichia coli K-12
cytosol30S ribosomal protein S10Escherichia coli K-12
ribosome30S ribosomal protein S10Escherichia coli K-12
cytoplasm30S ribosomal protein S10Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S10Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S10Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S10Escherichia coli K-12
cytosol30S ribosomal protein S11Escherichia coli K-12
ribosome30S ribosomal protein S11Escherichia coli K-12
cytoplasm30S ribosomal protein S11Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S11Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S11Escherichia coli K-12
cytosol30S ribosomal protein S12Escherichia coli K-12
ribosome30S ribosomal protein S12Escherichia coli K-12
cytoplasm30S ribosomal protein S12Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S12Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S12Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S12Escherichia coli K-12
ribosome30S ribosomal protein S12Escherichia coli K-12
cytosol30S ribosomal protein S13Escherichia coli K-12
ribosome30S ribosomal protein S13Escherichia coli K-12
cytoplasm30S ribosomal protein S13Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S13Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S13Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S13Escherichia coli K-12
cytosol30S ribosomal protein S13Escherichia coli K-12
cytoplasm30S ribosomal protein S16Escherichia coli K-12
ribosome30S ribosomal protein S16Escherichia coli K-12
intracellular organelle30S ribosomal protein S16Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S16Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S16Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S16Escherichia coli K-12
cytosol30S ribosomal protein S18Escherichia coli K-12
ribosome30S ribosomal protein S18Escherichia coli K-12
cytoplasm30S ribosomal protein S18Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S18Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S18Escherichia coli K-12
cytoplasm30S ribosomal protein S19Escherichia coli K-12
cytosol30S ribosomal protein S19Escherichia coli K-12
ribosome30S ribosomal protein S19Escherichia coli K-12
intracellular organelle30S ribosomal protein S19Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S19Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S19Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S19Escherichia coli K-12
cytosol30S ribosomal protein S20Escherichia coli K-12
ribosome30S ribosomal protein S20Escherichia coli K-12
cytoplasm30S ribosomal protein S20Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S20Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S20Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S20Escherichia coli K-12
cytosol30S ribosomal protein S20Escherichia coli K-12
ribosome30S ribosomal protein S2Escherichia coli K-12
cytoplasm30S ribosomal protein S2Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S2Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S2Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S2Escherichia coli K-12
cytosol30S ribosomal protein S3Escherichia coli K-12
ribosome30S ribosomal protein S3Escherichia coli K-12
cytoplasm30S ribosomal protein S3Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S3Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S3Escherichia coli K-12
cytosol30S ribosomal protein S4Escherichia coli K-12
ribosome30S ribosomal protein S4Escherichia coli K-12
cytoplasm30S ribosomal protein S4Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S4Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S4Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S4Escherichia coli K-12
cytoplasm30S ribosomal protein S5Escherichia coli K-12
cytosol30S ribosomal protein S5Escherichia coli K-12
ribosome30S ribosomal protein S5Escherichia coli K-12
intracellular organelle30S ribosomal protein S5Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S5Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S5Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S5Escherichia coli K-12
cytoplasm30S ribosomal protein S8Escherichia coli K-12
cytosol30S ribosomal protein S8Escherichia coli K-12
ribosome30S ribosomal protein S8Escherichia coli K-12
intracellular organelle30S ribosomal protein S8Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S8Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S8Escherichia coli K-12
cytosol30S ribosomal protein S9Escherichia coli K-12
ribosome30S ribosomal protein S9Escherichia coli K-12
intracellular organelle30S ribosomal protein S9Escherichia coli K-12
cytoplasm30S ribosomal protein S9Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S9Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S9Escherichia coli K-12
cytoplasm50S ribosomal protein L13Escherichia coli K-12
cytosol50S ribosomal protein L13Escherichia coli K-12
ribosome50S ribosomal protein L13Escherichia coli K-12
intracellular organelle50S ribosomal protein L13Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L13Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L13Escherichia coli K-12
ribosome50S ribosomal protein L13Escherichia coli K-12
cytosol50S ribosomal protein L14Escherichia coli K-12
ribosome50S ribosomal protein L14Escherichia coli K-12
cytoplasm50S ribosomal protein L14Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L14Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L14Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L14Escherichia coli K-12
ribosome50S ribosomal protein L16Escherichia coli K-12
cytoplasm50S ribosomal protein L16Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L16Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L16Escherichia coli K-12
ribosome50S ribosomal protein L23Escherichia coli K-12
cytoplasm50S ribosomal protein L23Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L23Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L23Escherichia coli K-12
cytoplasm30S ribosomal protein S15Escherichia coli K-12
cytosol30S ribosomal protein S15Escherichia coli K-12
ribosome30S ribosomal protein S15Escherichia coli K-12
intracellular organelle30S ribosomal protein S15Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S15Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S15Escherichia coli K-12
cytosol50S ribosomal protein L17Escherichia coli K-12
ribosome50S ribosomal protein L17Escherichia coli K-12
cytoplasm50S ribosomal protein L17Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L17Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L17Escherichia coli K-12
cytoplasm50S ribosomal protein L21Escherichia coli K-12
cytosol50S ribosomal protein L21Escherichia coli K-12
ribosome50S ribosomal protein L21Escherichia coli K-12
intracellular organelle50S ribosomal protein L21Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L21Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L21Escherichia coli K-12
ribosome50S ribosomal protein L30Escherichia coli K-12
cytoplasm50S ribosomal protein L30Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L30Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L30Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L30Escherichia coli K-12
cytosol50S ribosomal protein L6Escherichia coli K-12
ribosome50S ribosomal protein L6Escherichia coli K-12
cytoplasm50S ribosomal protein L6Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L6Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L6Escherichia coli K-12
cytoplasm30S ribosomal protein S14Escherichia coli K-12
ribosome30S ribosomal protein S14Escherichia coli K-12
intracellular organelle30S ribosomal protein S14Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S14Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S14Escherichia coli K-12
small ribosomal subunit30S ribosomal protein S14Escherichia coli K-12
ribosome30S ribosomal protein S17Escherichia coli K-12
cytoplasm30S ribosomal protein S17Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S17Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S17Escherichia coli K-12
cytoplasm30S ribosomal protein S1Escherichia coli K-12
ribosome30S ribosomal protein S1Escherichia coli K-12
membrane30S ribosomal protein S1Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S1Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S1Escherichia coli K-12
cytoplasm50S ribosomal protein L18Escherichia coli K-12
cytosol50S ribosomal protein L18Escherichia coli K-12
ribosome50S ribosomal protein L18Escherichia coli K-12
intracellular organelle50S ribosomal protein L18Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L18Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L18Escherichia coli K-12
cytosol50S ribosomal protein L2Escherichia coli K-12
ribosome50S ribosomal protein L2Escherichia coli K-12
cytoplasm50S ribosomal protein L2Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L2Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L2Escherichia coli K-12
DnaA-L2 complex50S ribosomal protein L2Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L2Escherichia coli K-12
cytosol50S ribosomal protein L3Escherichia coli K-12
ribosome50S ribosomal protein L3Escherichia coli K-12
cytoplasm50S ribosomal protein L3Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L3Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L3Escherichia coli K-12
cytosol50S ribosomal protein L24Escherichia coli K-12
ribosome50S ribosomal protein L24Escherichia coli K-12
cytoplasm50S ribosomal protein L24Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L24Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L24Escherichia coli K-12
cytosol50S ribosomal protein L4Escherichia coli K-12
ribosome50S ribosomal protein L4Escherichia coli K-12
cytoplasm50S ribosomal protein L4Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L4Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L4Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L4Escherichia coli K-12
cytosol50S ribosomal protein L22Escherichia coli K-12
ribosome50S ribosomal protein L22Escherichia coli K-12
cytoplasm50S ribosomal protein L22Escherichia coli K-12
large ribosomal subunit50S ribosomal protein L22Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L22Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L22Escherichia coli K-12
cytosol50S ribosomal protein L5Escherichia coli K-12
ribosome50S ribosomal protein L5Escherichia coli K-12
cytoplasm50S ribosomal protein L5Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L5Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L5Escherichia coli K-12
cytosol30S ribosomal protein S21Escherichia coli K-12
ribosome30S ribosomal protein S21Escherichia coli K-12
cytoplasm30S ribosomal protein S21Escherichia coli K-12
cytosolic small ribosomal subunit30S ribosomal protein S21Escherichia coli K-12
ribonucleoprotein complex30S ribosomal protein S21Escherichia coli K-12
cytosol50S ribosomal protein L25Escherichia coli K-12
ribosome50S ribosomal protein L25Escherichia coli K-12
cytoplasm50S ribosomal protein L25Escherichia coli K-12
cytosolic large ribosomal subunit50S ribosomal protein L25Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L25Escherichia coli K-12
ribosome50S ribosomal protein L36 2Escherichia coli K-12
cytosolic ribosome50S ribosomal protein L36 2Escherichia coli K-12
ribonucleoprotein complex50S ribosomal protein L36 2Escherichia coli K-12
nucleoplasmTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
cytoplasmTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
plasma membraneTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
intracellular membrane-bounded organelleTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
nucleusTyrosyl-DNA phosphodiesterase 1Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (403)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID394683Antibacterial activity against Pseudomonas aeruginosa clinical isolate by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID534173Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid MEZ by Etest method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID228036Percent of interaction with wheat germ tRNA (type V) at a concentration of 35 uM2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Study of aminoglycoside-nucleic acid interactions by an HPLC method.
AID404899Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB34 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID533588Antibacterial activity against gentamicin-resistant Staphylococcus epidermidis clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533356Antibacterial activity against non-gentamicin-resistant Pseudomonas aeruginosa clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID563873Antimicrobial activity against Escherichia coli 1515 using 2.4 X 10'6 CFU inoculum by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID357371Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by disk diffusion method2001Journal of natural products, Aug, Volume: 64, Issue:8
Samioside, a new phenylethanoid glycoside with free-radical scavenging and antimicrobial activities from Phlomis samia.
AID377029Antimicrobial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by disk diffusion assay2005Journal of natural products, Jan, Volume: 68, Issue:1
Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID1575869Inhibition of human mitochondrial ribosome Mit 13 hybridized with Mycobacterium smegmatis ribosome assessed as inhibition of translation activity using Firefly luciferase mRNA reporter based luminescence analysis2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID1575864Selectivity ratio of IC50 for inhibition of human cytoplasmic ribosome Cyt 14 hybridized with Mycobacterium smegmatis ribosomes to IC50 for inhibition of Mycobacterium smegmatis wild type ribosomes2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID563892Antimicrobial activity against Escherichia coli 9612 infected in new Zealand white rabbit with skin burn injury assessed as decrease in bacterial load in burn wound at 1 mg/ml after 24 hrs (Rvb = 8.57 +/- 0.35 log10CFU/g)2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID563888Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 15 infected in CD-1 ICR mouse using 2.5 X 10'5 CFU inoculum2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID158615IC50 was measured as concentration causing 50% inhibition of lysosomal phospholipase A1 activity.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID533329Antibacterial activity against non-gentamicin-resistant Klebsiella pneumoniae clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533341Antibacterial activity against non-gentamicin-resistant Haemophilus influenzae clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID68538Minimum inhibitory concentration (MIC) was measured against Enterobacter cloacae.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID567584Antimicrobial activity against Acinetobacter baumannii by broth dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID533594Antibacterial activity against gentamicin-resistant Citrobacter diversus clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID285580Antimicrobial activity against Pseudomonas aeruginosa IC7 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID533328Antibacterial activity against non-gentamicin-resistant Escherichia coli clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID405823Antimicrobial activity against Acinetobacter baumannii 9043 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID533333Antibacterial activity against non-gentamicin-resistant Proteus mirabilis clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID283535Antibacterial activity against Pseudomonas aeruginosa FE10U with inactivated nuoG and galU genes by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID405820Antimicrobial activity against Acinetobacter baumannii 501 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID533590Antibacterial activity against gentamicin-resistant Escherichia coli clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID563879Antimicrobial activity against Enterococcus faecalis ATCC 29212 using 2.8 X 10'7 by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID533586Antibacterial activity against gentamicin-resistant Pseudomonas spp. clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID533596Antibacterial activity against gentamicin-resistant Serratia marcescens clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID533599Antibacterial activity against gentamicin-resistant Proteus rettgeri clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1575872Antibacterial activity against Escherichia coli clinical isolate AG0032019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID533334Antibacterial activity against non-gentamicin-resistant Serratia marcescens clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID295855Antifungal activity against Aspergillus flavus at 300 ug/disc after 72 hrs by disk diffusion method2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents.
AID533582Antibacterial activity against gentamicin-resistant Citrobacter freundii clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID495512Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4666 by antimicrobial susceptibility assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID1575865Selectivity ratio of IC50 for inhibition of human mitochondrial ribosome Mit 13 A1555G mutant hybridized with Mycobacterium smegmatis ribosomes to IC50 for inhibition of Mycobacterium smegmatis wild type ribosomes2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID405455Antibacterial activity against Escherichia coli 1540 isolate by disk diffusion method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
AID428871Antibacterial activity against Escherichia coli CSH-2 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID533587Antibacterial activity against gentamicin-resistant Staphylococcus aureus clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533351Antibacterial activity against non-gentamicin-resistant Serratia marcescens clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1271376Antimicrobial activity against Gram-positive Bacillus anthracis str. Sterne after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID394701Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, ANT(2'')-1 by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID357368Antimicrobial activity against Enterobacter cloacae ATCC 13047 by disk diffusion method2001Journal of natural products, Aug, Volume: 64, Issue:8
Samioside, a new phenylethanoid glycoside with free-radical scavenging and antimicrobial activities from Phlomis samia.
AID530349Antimicrobial activity against Escherichia coli TOP10 harboring pQep plasmid carrying qepA2 gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID523396Antimicrobial activity against amikacin-resistant Nocardia farcinica IFM 10580 after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID533344Antibacterial activity against non-gentamicin-resistant Staphylococcus epidermidis clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID295861Antifungal activity against Trichophyton mentagrophytes at 300 ug/disc after 72 hrs by disk diffusion method2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents.
AID495515Antibacterial activity against Acinetobacter baumannii CIP70-10 by antimicrobial susceptibility assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID404898Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB33 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID357366Antimicrobial activity against Staphylococcus aureus ATCC 25923 by disk diffusion method2001Journal of natural products, Aug, Volume: 64, Issue:8
Samioside, a new phenylethanoid glycoside with free-radical scavenging and antimicrobial activities from Phlomis samia.
AID283530Antibacterial activity against Pseudomonas aeruginosa FE10 with inactivated nuoG gene by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID522929Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase N196D/D268N mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID394714Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as susceptible rate by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID533332Antibacterial activity against non-gentamicin-resistant Citrobacter diversus clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1631084Inhibition of TDP1 (unknown origin) using 14-mer duplex oligonucleotide [32P]-D14Y as substrate incubated for 20 mins by PAGE analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential.
AID533353Antibacterial activity against non-gentamicin-resistant Citrobacter freundii clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID530347Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M carrying blaCTX-M-15 and pQep plasmid carrying qepA2 gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID283541Antibacterial activity against Pseudomonas aeruginosa FE53GU with inactivated mexZ, nuoG and galU genes by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID405824Antimicrobial activity against Acinetobacter baumannii 696 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID560599Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid expressing aac(6')-Iaf wild type gene by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID533340Antibacterial activity against non-gentamicin-resistant Pseudomonas spp. clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533591Antibacterial activity against gentamicin-resistant Klebsiella pneumoniae clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533337Antibacterial activity against non-gentamicin-resistant Proteus rettgeri clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID65065Percent killing of the total Escherichia coli K12 (ATCC 25868) cells at the C50 concentration was determined.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID530348Antimicrobial activity against azide-resistant Escherichia coli J53 by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID533331Antibacterial activity against non-gentamicin-resistant Enterobacter aerogenes clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533626Phosphorylation activity of AAC(6')-APH(2'') in Escherichia coli BL21(DE3) assessed as oxidation of NADH by pyruvate kinase relative to verdamicin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1575868Inhibition of human cytoplasmic ribosome Cyt 14 hybridized with Mycobacterium smegmatis ribosome assessed as inhibition of translation activity using Firefly luciferase mRNA reporter based luminescence analysis2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID163280Minimum inhibitory concentration (MIC) was measured against Pseudomonas aeruginosa.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID1575874Antibacterial activity against Escherichia coli clinical isolate AG0012019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID533330Antibacterial activity against non-gentamicin-resistant Enterobacter cloacae clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533585Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID357378Antimicrobial activity against Escherichia coli ATCC 25922 by agar dilution method2001Journal of natural products, Aug, Volume: 64, Issue:8
Samioside, a new phenylethanoid glycoside with free-radical scavenging and antimicrobial activities from Phlomis samia.
AID65059Concentration required for half maximum rate of enhanced [3H]DHS uptake in Escherichia coli K121987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID1271384Antimicrobial activity against Gram-negative Pseudomonas aeruginosa PAO1 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID533574Antibacterial activity against gentamicin-resistant Escherichia coli clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID563890Antimicrobial activity against Enterococcus faecalis HH22 infected in CD-1 ICR mouse using 1.8 X 10'8 inoculum2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID533343Antibacterial activity against non-gentamicin-resistant Staphylococcus aureus clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID534166Antimicrobial activity against rmtB positive Escherichia coli VOG producing beta lactamase CTX-M-14 by Etest method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID533576Antibacterial activity against gentamicin-resistant Enterobacter cloacae clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533350Antibacterial activity against non-gentamicin-resistant Proteus mirabilis clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID285606Antimicrobial activity against Pseudomonas aeruginosa 2A7 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID498872Antimicrobial activity against Acinetobacter baumannii B9 containing carbapenemase blaOXA-23 gene assessed as growth inhibition by Etest method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
First isolation of the blaOXA-23 carbapenemase gene from an environmental Acinetobacter baumannii isolate.
AID563889Antimicrobial activity against Enterococcus faecalis ATCC 29212 infected in CD-1 ICR mouse using 2.8 X 10'7 inoculum2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID560591Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ799 by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID404900Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB40 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID533589Antibacterial activity against gentamicin-resistant Enterococcus faecalis clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID283546Antibacterial activity against Pseudomonas aeruginosa KJ7106 with inactivated PA5471 gene by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID405816Antimicrobial activity against Escherichia coli DH5alpha harboring recombinant pIMPAR312007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID203165Minimum inhibitory concentration measured against Serratia marcescens1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID534174Antimicrobial activity against armA positive Enterobacter cloacae BEH producing beta lactamase CTX-M-3 by Etest method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID533584Antibacterial activity against gentamicin-resistant Acinetobacter calcoaceticus clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID163279Minimum inhibitory concentration (MIC) was measured against Pseudomonas aeruginosa ATCC 27853.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID295857Antifungal activity against Aspergillus variecolor at 300 ug/disc after 72 hrs by disk diffusion method2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents.
AID206015Minimum inhibitory concentration (MIC) was measured against Staphylococcus aureus ATCC 25923.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID533335Antibacterial activity against non-gentamicin-resistant Morganella morganii clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID285589Antimicrobial activity against Pseudomonas aeruginosa 65.36-4 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID523066Antibacterial activity against Escherichia coli JM83 harboring empty pHF022 vector by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID1575873Antibacterial activity against Escherichia coli clinical isolate AG0552019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID69665Minimum inhibitory concentration (MIC) was measured against Escherichia coli. 1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID1575860Antibacterial activity against Pseudomonas aeruginosa clinical isolate AG0322019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID534178Antimicrobial activity against Escherichia coli TOP10 by Etest method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID283547Antibacterial activity against Pseudomonas aeruginosa FE60 containing inactivated mexXY gene by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID533601Antibacterial activity against gentamicin-resistant Pseudomonas aeruginosa clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533592Antibacterial activity against gentamicin-resistant Enterobacter cloacae clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID522930Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase R92H/D268N mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID533578Antibacterial activity against gentamicin-resistant Citrobacter diversus clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533338Antibacterial activity against non-gentamicin-resistant Acinetobacter calcoaceticus clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID285600Antimicrobial activity against Pseudomonas aeruginosa 2C2 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID530345Antimicrobial activity against Escherichia coli BicA expressing blaTEM-1, blaCTX-M-15 and qepA2 gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID50539Minimum inhibitory concentration (MIC) was measured against Citrobacter freundii.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID495518Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4676 by antimicrobial susceptibility assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID1557358Antiviral activity against HIV1 NL4-3 infected human TZM-bl cells assessed as reduction in viral replication2019MedChemComm, Aug-01, Volume: 10, Issue:8
Synthetic small-molecule RNA ligands: future prospects as therapeutic agents.
AID567582Antimicrobial activity against Acinetobacter baumannii assessed as susceptible isolate by broth dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID495516Antibacterial activity against multidrug-resistant Acinetobacter baumannii AYE by antimicrobial susceptibility assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID283544Antibacterial activity against Pseudomonas aeruginosa FE57GZ with inactivated rplY, nuoG and mexZ genes by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID533573Antibacterial activity against non-gentamicin-resistant Staphylococcus epidermidis clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID529457Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone B expressing beta-lactamase Oxa-48, TEM-1, CTX-M-15 and Oxa-1 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID534175Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid BEH by Etest method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID495509Antibacterial activity against Acinetobacter baumannii BM4587 by antimicrobial susceptibility assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID563875Antimicrobial activity against Klebsiella pneumoniae 967 using 2.6 X 10'5 CFU inoculum by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID533339Antibacterial activity against non-gentamicin-resistant Pseudomonas aeruginosa clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID522931Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a phosphotransferase R92H mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID283536Antibacterial activity against Pseudomonas aeruginosa FE53U with inactivated mexZ and galU genes by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID283533Antibacterial activity against Pseudomonas aeruginosa FE57 with inactivated rplY gene by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID394702Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(6')-1 by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID533336Antibacterial activity against non-gentamicin-resistant Citrobacter freundii clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID283540Antibacterial activity against Pseudomonas aeruginosa FE57Z with inactivated rplY and mexZ genes by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID533580Antibacterial activity against gentamicin-resistant Serratia marcescens clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID394704Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing AAC(6')-1, ANT(2'')-1 by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID405825Antimicrobial activity against Acinetobacter baumannii 694 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID357369Antimicrobial activity against Escherichia coli ATCC 25922 by disk diffusion method2001Journal of natural products, Aug, Volume: 64, Issue:8
Samioside, a new phenylethanoid glycoside with free-radical scavenging and antimicrobial activities from Phlomis samia.
AID1271382Antimicrobial activity against Gram-positive methicillin-resistant Staphylococcus aureus 2 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID283538Antibacterial activity against Pseudomonas aeruginosa FE53G with inactivated mexZ and nuoG genes by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID533581Antibacterial activity against gentamicin-resistant Morganella morganii clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1575861Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate AG042 harboring with ANT4',4\\\\\\\\\\ gene2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID1271381Antimicrobial activity against Gram-positive methicillin-resistant Staphylococcus aureus 1 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID1271377Antimicrobial activity against Gram-positive Bacillus cereus ATCC 17788 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID357583Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by agar dilution method2001Journal of natural products, Aug, Volume: 64, Issue:8
Samioside, a new phenylethanoid glycoside with free-radical scavenging and antimicrobial activities from Phlomis samia.
AID529456Antimicrobial activity against Klebsiella pneumoniae containing PFGE clone A expressing beta-lactamase Oxa-48, TEM-1, SHV-12 and Oxa-9 by Etest2008Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8
Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey.
AID533349Antibacterial activity against non-gentamicin-resistant Citrobacter diversus clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID523397Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID533342Antibacterial activity against non-gentamicin-resistant Haemophilus parainfluenzae clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID285608Antimicrobial activity against Pseudomonas aeruginosa 3B1 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID533600Antibacterial activity against gentamicin-resistant Acinetobacter calcoaceticus clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533575Antibacterial activity against gentamicin-resistant Klebsiella pneumoniae clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID428873Antibacterial activity against Escherichia coli JM109 carrying pMCL210 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID394700Antibacterial activity against MexXY-OprM pump-independent aminoglycoside-resistant Pseudomonas aeruginosa isolate by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID533577Antibacterial activity against gentamicin-resistant Enterobacter aerogenes clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID93906Minimum inhibitory concentration (MIC) was measured against Klebsiella pneumoniae.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID563885Antimicrobial activity against Klebsiella pneumoniae 967 infected in CD-1 ICR mouse using 2.6 X 10'5 CFU inoculum2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID285575Antimicrobial activity against Pseudomonas aeruginosa 65.18-2 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID534171Antimicrobial activity against beta lactamase CTX-M-14 producing Escherichia coli TOP10 harboring plasmid COP2 by Etest method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID394708Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing AAC(6')-1 by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID283534Antibacterial activity against Pseudomonas aeruginosa FE57 containing inactivated rplY gene with pARAL25 by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID404902Antimicrobial activity against Enterococcus faecalis ATCC 29212 by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID405819Antimicrobial activity against Acinetobacter sp. 5227 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID563871Antimicrobial activity against Escherichia coli ATCC 25922 using 1 X 10'5 CFU inoculum by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID522932Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a N196D mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID533598Antibacterial activity against gentamicin-resistant Citrobacter freundii clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1271380Antimicrobial activity against Gram-positive Staphylococcus aureus ATCC 29213 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID283545Antibacterial activity against Pseudomonas aeruginosa FE57GUZ with inactivated rplY, nuoG, galU and mexZ genes by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID404895Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB10 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID533583Antibacterial activity against gentamicin-resistant Proteus rettgeri clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1271385Antimicrobial activity against Mycobacterium smegmatis MC2-155 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID69666Minimum inhibitory concentration (MIC) was measured against Escherichia coli ATCC 25922.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID394706Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(3')-1 by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID283539Antibacterial activity against Pseudomonas aeruginosa FE57G with inactivated rplY and nuoG genes by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID560600Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid expressing aac(6')-Iaf (TTG-ATG) mutant gene by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID530346Antimicrobial activity against azide-resistant Escherichia coli J53 harboring pCTX-M plasmid carrying blaCTX-M-15 gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID495517Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4675 by antimicrobial susceptibility assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID560598Antimicrobial activity against Escherichia coli JM109 transformant harboring pSTV28 plasmid by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID534169Antimicrobial activity against armB positive Escherichia coli COP producing beta lactamase CTX-M-14 by Etest method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1575859Antibacterial activity against Pseudomonas aeruginosa clinical isolate AG0332019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID1271379Antimicrobial activity against Gram-positive Listeria monocytogenes ATCC 19115 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID533579Antibacterial activity against gentamicin-resistant Proteus mirabilis clinical isolate after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID394699Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID357376Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 by agar dilution method2001Journal of natural products, Aug, Volume: 64, Issue:8
Samioside, a new phenylethanoid glycoside with free-radical scavenging and antimicrobial activities from Phlomis samia.
AID377032Antimicrobial activity against Enterobacter cloacae ATCC 13047 after 24 hrs by disk diffusion assay2005Journal of natural products, Jan, Volume: 68, Issue:1
Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID533605Antibacterial activity against gentamicin-resistant Enterococcus faecalis clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1575866Selectivity ratio of IC50 for inhibition of human mitochondrial ribosome Mit 13 hybridized with Mycobacterium smegmatis ribosome to IC50 for inhibition of Mycobacterium smegmatis wild type ribosomes2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID523398Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 harboring 16s rRNA A1408G mutant after 5 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID357375Antimicrobial activity against Staphylococcus aureus ATCC 25923 by agar dilution method2001Journal of natural products, Aug, Volume: 64, Issue:8
Samioside, a new phenylethanoid glycoside with free-radical scavenging and antimicrobial activities from Phlomis samia.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1575862Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate AG0382019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID285599Antimicrobial activity against Pseudomonas aeruginosa 2A2 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID522928Antibacterial activity against Escherichia coli JM83 producing aminoglycoside 2''-2a phosphotransferase by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID285578Antimicrobial activity against Pseudomonas aeruginosa P21.23 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID283531Antibacterial activity against Pseudomonas aeruginosa FE49 with inactivated galU gene by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID563876Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 using 1.5 X 10'5 CFU inoculum by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID69667Minimum inhibitory concentration (MIC) was measured against Escherichia coli ATCC 35218.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID285573Antimicrobial activity against Pseudomonas aeruginosa P21.21 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID563880Antimicrobial activity against Enterococcus faecalis HH22 using 1.8 X 10'8 by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID283537Antibacterial activity against Pseudomonas aeruginosa FE57U with inactivated rplY and galU genes by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID357367Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 by disk diffusion method2001Journal of natural products, Aug, Volume: 64, Issue:8
Samioside, a new phenylethanoid glycoside with free-radical scavenging and antimicrobial activities from Phlomis samia.
AID283532Antibacterial activity against Pseudomonas aeruginosa FE53 with inactivated mexZ gene by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID533357Antibacterial activity against non-gentamicin-resistant Pseudomonas spp. clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1575870Inhibition of Mycobacterium smegmatis wild type ribosomes assessed as inhibition of translation activity using Firefly luciferase mRNA reporter based luminescence analysis2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID404896Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB28 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID563886Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 infected in CD-1 ICR mouse using 1.5 X 10'5 CFU inoculum2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID285593Antimicrobial activity against Pseudomonas aeruginosa 65.38-4 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID404901Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB41 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID523405Antimicrobial activity against amikacin-susceptible Nocardia farcinica IFM 10152 after 3 days by broth microdilution method2010Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6
Homozygous triplicate mutations in three 16S rRNA genes responsible for high-level aminoglycoside resistance in Nocardia farcinica clinical isolates from a Canada-wide bovine mastitis epizootic.
AID563884Antimicrobial activity against Klebsiella pneumoniae 935 infected in CD-1 ICR mouse using 3 X 10'5 CFU inoculum2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID563874Antimicrobial activity against Klebsiella pneumoniae 935 using 3 X 10'5 CFU inoculum by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID563877Antimicrobial activity against methicillin-resistant Staphylococcus aureus 9344 using 2.5 X 10'5 CFU inoculum by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID295859Antifungal activity against Trichophyton rubrum at 300 ug/disc after 72 hrs by disk diffusion method2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents.
AID67885Minimum inhibitory concentration (MIC) was measured against Enterococcus faecalis ATCC 29212.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID533354Antibacterial activity against non-gentamicin-resistant Proteus rettgeri clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID285609Antimicrobial activity against Pseudomonas aeruginosa 65.68-1 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID533346Antibacterial activity against non-gentamicin-resistant Klebsiella pneumoniae clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID357582Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 by agar dilution method2001Journal of natural products, Aug, Volume: 64, Issue:8
Samioside, a new phenylethanoid glycoside with free-radical scavenging and antimicrobial activities from Phlomis samia.
AID285595Antimicrobial activity against Pseudomonas aeruginosa 1B9 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID563872Antimicrobial activity against Escherichia coli 9612 using 3.7 X 10'4 CFU inoculum by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID285610Antimicrobial activity against Pseudomonas aeruginosa 65.68-2 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1575863Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate AG0392019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID1271383Antimicrobial activity against Gram-negative Haemophilus influenzae ATCC 51907 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID428870Antibacterial activity against Escherichia coli CSH-2 carrying Escherichia coli ARS3 pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID495514Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4668 by antimicrobial susceptibility assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID285577Antimicrobial activity against Pseudomonas aeruginosa 65.18-4 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID404903Antibacterial activity against Streptococcus bovis ATCC 33317 by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID285597Antimicrobial activity against Pseudomonas aeruginosa 2A1 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID533345Antibacterial activity against non-gentamicin-resistant Escherichia coli clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533604Antibacterial activity against gentamicin-resistant Staphylococcus epidermidis clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533571Antibacterial activity against non-gentamicin-resistant Haemophilus parainfluenzae clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID394703Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing ANT(2'')-1 by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID533593Antibacterial activity against gentamicin-resistant Enterobacter aerogenes clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533595Antibacterial activity against gentamicin-resistant Proteus mirabilis clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID285591Antimicrobial activity against Pseudomonas aeruginosa 65.38-2 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID534170Antimicrobial activity against armA positive Escherichia coli TOP10 harboring plasmid COP1 by Etest method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID285601Antimicrobial activity against Pseudomonas aeruginosa 2A3 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID563881Antimicrobial activity against Escherichia coli ATCC 25922 infected in CD-1 ICR mouse using 1 X 10'5 CFU inoculum2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID394685Antibacterial activity against wild type Pseudomonas aeruginosa isolate by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID1271378Antimicrobial activity against Gram-positive Bacillus subtilis 168 after 16 to 24 hrs by micro-dilution method2015ACS medicinal chemistry letters, Nov-12, Volume: 6, Issue:11
Synthesis and Biological Activity of Mono- and Di-N-acylated Aminoglycosides.
AID563887Antimicrobial activity against methicillin-resistant Staphylococcus aureus 9344 infected in CD-1 ICR mouse using 2.5 X 10'5 CFU inoculum2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID522933Antibacterial activity against Escherichia coli JM83 harboring pHF022 containing aminoglycoside 2''-2a D268N mutant by broth microdilution method2010Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4
Mutant APH(2'')-IIa enzymes with increased activity against amikacin and isepamicin.
AID428869Antibacterial activity against Escherichia coli isolate ARS3 carrying pARS3 by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID65062Lethal dose required to kill 90% of the Escherichia coli K12 (ATCC 25868) cell population1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID283549Antibacterial activity against Pseudomonas aeruginosa FE64 containing inactivated rplY and mexXY genes by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID220347Percent of interaction with calf thymus DNA (activated type XV) at a concentration of 35 uM2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
Study of aminoglycoside-nucleic acid interactions by an HPLC method.
AID495511Antibacterial activity against multidrug-resistant Acinetobacter baumannii BM4665 by antimicrobial susceptibility assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID534168Antimicrobial activity against Escherichia coli TOP10 harboring plasmid VOG2 expressing CTX-M-14 and AAC(6 )-Ib gene by Etest method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID405818Antimicrobial activity against Acinetobacter sp. 5248 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID394684Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID405821Antimicrobial activity against Acinetobacter baumannii 695 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID30415Minimum inhibitory concentration (MIC) was measured against Acinetobacter lwoffi ATCC 17986.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID534176Antimicrobial activity against armA positive Klebsiella pneumoniae DU producing beta lactamase CTX-M-3 by Etest method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID285605Antimicrobial activity against Pseudomonas aeruginosa 2F6 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID285579Antimicrobial activity against Pseudomonas aeruginosa IA5 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID283548Antibacterial activity against Pseudomonas aeruginosa FE63 containing inactivated rplY and PA5471 genes by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID563882Antimicrobial activity against Escherichia coli 9612 infected in CD-1 ICR mouse using 3.7 X 10'4 CFU inoculum2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID534167Antimicrobial activity against Escherichia coli TOP10 harboring plasmid VOG1 expressing RmtB, TEM-1, and QepA gene by Etest method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID533627Ratio of Vmax to Km for AAC(6')-APH(2'') in Escherichia coli BL21(DE3) assessed as oxidation of NADH by pyruvate kinase relative to netilmicin2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID285602Antimicrobial activity against Pseudomonas aeruginosa 2A5 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID533602Antibacterial activity against gentamicin-resistant Pseudomonas spp. clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID285598Antimicrobial activity against Pseudomonas aeruginosa 2C1 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID533348Antibacterial activity against non-gentamicin-resistant Enterobacter aerogenes clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID534177Antimicrobial activity against armA positive Escherichia coli TOP10 producing beta lactamase CTX-M-3 with plasmid DU by Etest method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID285576Antimicrobial activity against Pseudomonas aeruginosa 65.18-3 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID377031Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 after 24 hrs by disk diffusion assay2005Journal of natural products, Jan, Volume: 68, Issue:1
Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID405817Antimicrobial activity against Pseudomonas putida 12346 isolate harboring bla IMP-1 carrying integron In86 containing aminoglycoside resistance gene aac(6')-32007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID533570Antibacterial activity against non-gentamicin-resistant Haemophilus influenzae clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID285594Antimicrobial activity against Pseudomonas aeruginosa 1A9 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID1575867Inhibition of human mitochondrial ribosome Mit 13 A1555G mutant hybridized with Mycobacterium smegmatis ribosome assessed as inhibition of translation activity using Firefly luciferase mRNA reporter based luminescence analysis2019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID30395Minimum inhibitory concentration (MIC) was measured against Acinetobacter baumanni ATCC 19606.1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID357370Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 by disk diffusion method2001Journal of natural products, Aug, Volume: 64, Issue:8
Samioside, a new phenylethanoid glycoside with free-radical scavenging and antimicrobial activities from Phlomis samia.
AID495510Antibacterial activity against Acinetobacter baumannii BM4454 by antimicrobial susceptibility assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID563883Antimicrobial activity against Escherichia coli 1515 infected in CD-1 ICR mouse using 2.4 X 10'6 CFU inoculum2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID377033Antimicrobial activity against Escherichia coli ATCC 25922 after 24 hrs by disk diffusion assay2005Journal of natural products, Jan, Volume: 68, Issue:1
Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID206014Minimum inhibitory concentration (MIC) was measured against Staphylococcus aureus. 1995Journal of medicinal chemistry, Nov-10, Volume: 38, Issue:23
Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin.
AID285590Antimicrobial activity against Pseudomonas aeruginosa 65.38-1 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID394707Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(6')-1, AAC(3')-1 by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID534172Antimicrobial activity against armA positive Escherichia coli MEZ producing beta lactamase CTX-M-3 by Etest method2008Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12
Plasmid-mediated 16S rRNA methylases among extended-spectrum beta-lactamase-producing Enterobacteriaceae isolates.
AID1575871Antibacterial activity against Pseudomonas aeruginosa clinical isolate AG0312019MedChemComm, Jun-01, Volume: 10, Issue:6
Synthesis, ribosomal selectivity, and antibacterial activity of netilmicin 4'-derivatives.
AID428872Antibacterial activity against Escherichia coli JM109 carrying pMCL-BE by agar dilution method2007Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides.
AID530350Antimicrobial activity against Escherichia coli TOP10 by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID377030Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 after 24 hrs by disk diffusion assay2005Journal of natural products, Jan, Volume: 68, Issue:1
Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID394682Antibacterial activity against Pseudomonas aeruginosa clinical isolates assessed as resistant rate by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID285596Antimicrobial activity against Pseudomonas aeruginosa 1C9 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID533625Phosphorylation activity of AAC(6')-APH(2'') in Escherichia coli BL21(DE3) assessed as oxidation of NADH by pyruvate kinase2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID283542Antibacterial activity against Pseudomonas aeruginosa FE57GU with inactivated rplY, nuoG and galU genes by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID567580Antimicrobial activity against Acinetobacter baumannii assessed as resistant isolate by broth dilution method2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii.
AID357377Antimicrobial activity against Enterobacter cloacae ATCC 13047 by agar dilution method2001Journal of natural products, Aug, Volume: 64, Issue:8
Samioside, a new phenylethanoid glycoside with free-radical scavenging and antimicrobial activities from Phlomis samia.
AID533572Antibacterial activity against non-gentamicin-resistant Staphylococcus aureus clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID533352Antibacterial activity against non-gentamicin-resistant Morganella morganii clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1557357Binding affinity to HIV1 TAR RNA in HIV1 NL4-3 infected human TZM-bl cells assessed as inhibition of Tat-mediated activation relative to control2019MedChemComm, Aug-01, Volume: 10, Issue:8
Synthetic small-molecule RNA ligands: future prospects as therapeutic agents.
AID533355Antibacterial activity against non-gentamicin-resistant Acinetobacter calcoaceticus clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID285582Antimicrobial activity against Pseudomonas aeruginosa 65.33-1 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID495513Antibacterial activity against Acinetobacter baumannii BM4467 by antimicrobial susceptibility assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Screening and quantification of the expression of antibiotic resistance genes in Acinetobacter baumannii with a microarray.
AID563878Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 15 using 2.5 X 10'5 CFU inoculum by agar dilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
In vivo antibacterial activity of vertilmicin, a new aminoglycoside antibiotic.
AID285592Antimicrobial activity against Pseudomonas aeruginosa 65.38-3 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID285607Antimicrobial activity against Pseudomonas aeruginosa 2A9 tracheal isolates from mechanically ventilated tuberculosis patient2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
AID533347Antibacterial activity against non-gentamicin-resistant Enterobacter cloacae clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1557356Binding affinity to HIV1 TAR RNA2019MedChemComm, Aug-01, Volume: 10, Issue:8
Synthetic small-molecule RNA ligands: future prospects as therapeutic agents.
AID533622Acetylation activity of AAC(6')-APH(2'') in Escherichia coli BL21(DE3) assessed as production of free pyridine-4-thiolate2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID540237Phospholipidosis-positive literature compound observed in rat
AID405822Antimicrobial activity against Escherichia coli DH5alpha2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6')-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID644960Displacement of ethidium bromide from human pre-hsa-mir-155 miRNA after 30 mins2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Pre-microRNA binding aminoglycosides and antitumor drugs as inhibitors of Dicer catalyzed microRNA processing.
AID65071Estimated rate of [3H]DHS uptake in Escherichia coli K12 (ATCC 25868)1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Comparison of aminoglycoside antibiotics with respect to uptake and lethal activity in Escherichia coli.
AID283543Antibacterial activity against Pseudomonas aeruginosa FE57UZ with inactivated rplY, galU and mexZ genes by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID283529Antibacterial activity against Pseudomonas aeruginosa PAO1 by microdilution method2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Cumulative effects of several nonenzymatic mechanisms on the resistance of Pseudomonas aeruginosa to aminoglycosides.
AID560590Antimicrobial activity against Pseudomonas aeruginosa isolate IMCJ798 by microdilution method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
AAC(6')-Iaf, a novel aminoglycoside 6'-N-acetyltransferase from multidrug-resistant Pseudomonas aeruginosa clinical isolates.
AID533603Antibacterial activity against gentamicin-resistant Staphylococcus aureus clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID533597Antibacterial activity against gentamicin-resistant Morganella morganii clinical isolate assessed as susceptible isolates after 18 hrs by agar dilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
In vitro antibacterial activity of vertilmicin and its susceptibility to modifications by the recombinant AAC6'-APH2'' enzyme.
AID404897Antibacterial activity against high-level gentamicin resistant Streptococcus pasteurianus SB30 isolate carrying transposon-borne resistance gene [aac(6')Ie-aph(2'')Ia] by agar dilution method2007Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7
High-level gentamicin resistance mediated by a Tn4001-like transposon in seven nonclonal hospital isolates of Streptococcus pasteurianus.
AID394705Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa isolate expressing MexXY-OprM pump, AAC(6')-1, ANT(2'')-1 by macrodilution technique2007Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
AID377035Antimicrobial activity against Klebsiella pneumoniae ATCC 13883 after 24 hrs by disk diffusion assay2005Journal of natural products, Jan, Volume: 68, Issue:1
Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,001)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990559 (55.84)18.7374
1990's235 (23.48)18.2507
2000's134 (13.39)29.6817
2010's55 (5.49)24.3611
2020's18 (1.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 58.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index58.16 (24.57)
Research Supply Index7.17 (2.92)
Research Growth Index4.20 (4.65)
Search Engine Demand Index100.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (58.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials190 (17.15%)5.53%
Trials0 (0.00%)5.53%
Reviews34 (3.07%)6.00%
Reviews0 (0.00%)6.00%
Case Studies78 (7.04%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other806 (72.74%)84.16%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus (Relais Oral Dans le Traitement Des Endocardites à Streptocoques Multi-sensibles) [NCT02701595]Phase 3324 participants (Anticipated)Interventional2016-02-29Recruiting
Comparison of Two Lengths of Treatment in Early-onset Ventilated Associated Pneumonia [NCT01559753]Phase 4225 participants (Actual)Interventional1998-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]